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Abstract 
Human neutrophil elastase, as inflammatory response, has the capacity to degrade 
collagen and elastin component of extracellular matrix, being extensively involved in 
wrinkles formation induced by UV radiation damage. In order to develop a cosmetic anti-
wrinkling emulsion, we incorporated a potent synthetic HNE inhibitor, sivelestat (IC50 = 44 
nM, Ki = Ͳ.ʹ μM), into biopolymeric nanoparticles prepared by high-energy emulsification 
methods. As nanomaterial was used Bombyx mori silk fibroin protein, an FDA approved 
natural biocompatible and biodegradable polymer. 
Silk fibroin nanoparticles (SF-NPs) were produced by two high-energy emulsification 
methods, ultrasonication and high pressure homogenization (HPH), in oil-in-water (o/w) 
emulsions using as n-dodecane as oil phase. According to optimized results, best 
formulations were obtained for 10 g/L of SF at 20/80 of o/w ratio at 22 cycles of 
homogenization by double-stage HPH (APV-ʹͲͲͲ™). During the NPs production by HPH 
emulsification process, the secondary SF structure changed from random-coil conformation to a more stable structure, Ⱦ-sheets. 
Stabilizers effect was also studied, namely poloxamer 407, transcutol, tween 80 and 
sodium dodecyl sulfate (SDS), in which the results suggested that combination of transcutol 
and SDS would effectively stabilize the SF-NPs over time. To predict the sivelestat 
incorporation, orange IV was used as a model-drug, being this incorporated into SF-NPs at 
different concentrations. Release studies of orange IV were evaluated in absence and 
presence of 0.5 U/mL of HNE. The release of orange IV at 100 µM from SF-NPs 
(concentration considered as optimal) showed to be controlled at some extent, in which the 
drug transport mechanism showed to be anomalous (Fickian diffusion and polymer 
degradation/relaxation) and not affected by 0.5 U/mL of HNE enzyme. 
Finally, the incorporation of 100 µM of sivelestat in SF-NPs performed with a 
formation and encapsulation efficiency of 99% and 50%, respectively, successfully inhibited 
the HNE enzyme, enhancing the potential of this drug delivery system for topical anti-
wrinkling application. 
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Resumo 
Elastase de Neutrófilos Humana, como resposta inflamatória, possui a capacidade de 
degradar os componentes da matriz extracelular, nomeadamente colagénio e elastina, 
estando envolvida na formação de rugas causadas pela radiação ultravioleta. De forma a 
desenvolver uma emulsão cosmética antirrugas, decidiu-se incorporar um potente inibidor 
sintético de elastase, sivelestat (IC50 = 44 nM, Ki = Ͳ,ʹ μM), em nanopartículas biopoliméricas 
formadas por métodos de emulsificação de elevada energia. Como nanomaterial usou-se a 
proteína fibroína de seda extraída do bicho-da-seda Bombyx mori, que é um polímero 
natural biocompatível e biodegradável aprovado pela FDA. 
As nanopartículas de fibroína de seda foram produzidas por dois métodos de 
emulsificação, ultrasonicação e homogeneização de elevada pressão, com emulsões óleo-
em-água, tendo-se usado n-dodecano como fase oleosa. De acordo com os resultados 
otimizados, a melhor formulação foi obtida com 10 g/L de fibroína de seda numa razão 
óleo/água de 20/80 a 22 ciclos de homogeneização, através do método de duplo-sistema de 
homogeneização de elevada pressão (APV-ʹͲͲͲ™). Nestas condições, durante a produção 
de nanopartículas nestas condições, a estrutura secundária aleatória da proteína de fibroína 
de seda sofreu uma alteração conformacional para uma estrutura mais estável, em folhas Ⱦeta. 
O efeito de estabilizadores na nanoemulsão foi também estudado, nomeadamente 
poloxamer 407, transcutol, tween 80 e dodecil sulfato de sódio, em que os resultados 
obtidos sugerem que a combinação de transcutol e dodecil sulfato de sódio estabilizaria 
eficientemente as nanopartículas de fibroína de seda ao longo do tempo. Para prever a 
incorporação de sivelestat, o corante orange IV foi utilizado como composto modelo, tendo 
sido incorporado nas nanopartículas de fibroína de seda a várias concentrações, e tendo-se 
estudado a sua libertação na ausência e na presença de elastase (0,5 U/mL). A libertação de 
orange IV das nanopartículas de fibroína de seda, numa concentração de 100 µM 
(concentração otimizada), exibiu um mecanismo de transporte controlado, tendo este sido 
definido como anómalo (difusão de Fickian e degradação/relaxamento do polímero) e não 
mostrou ser influenciada pela elastase (0,5 U/mL). 
Finalmente, incorporação de 100 µM de sivelestat nas nanopartículas de fibroína de 
seda que indicou uma eficiência de formação e de encapsulação de 99% e 50%, 
respetivamente, inibiu a enzima elastase de forma eficaz, evidenciando o potencial deste 
nanosistema como cosmético antirrugas para aplicação transdérmica. 
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Chapter I. Introduction 
 
1. Major Goals and Outline 
 
The emerging of nanotechnology in association with biotechnology has provided 
tools for development and innovation of science-based solutions, leading major 
breakthroughs in science (Morganti, 2010;Reis et al., 2006). In detail, bionanotechnology 
involves the interface of nanotechnology systems with biological and biochemical 
applications (Morganti, 2010). 
According to the European Commission, the financing for development of 
nanomaterials and production of innovative nanotechnologies has increased nearly 40% in 
the last six years, being associated to an increase of about 3.5 billion of euros (Morganti, 
2010). In fact, due to their potential uses and benefits, the bionanotechnology methods are 
already extensively used in medicine and pharmaceutical industry, being also used for 
cosmetic industry (Morganti, 2010).  
More specifically, bionanotechnology in cosmetic industry has been widely used since 
it improves their ability to penetrate the skin and have shown beneficial to the skin (Buzea 
et al., 2007;Grebler et al., 2010;Morganti, 2010;Patel et al., 2011;Roy et al., 2012). 
Additionally, considering the creativity, innovation, competitively and entrepreneurship 
involved in this area, it is thought to broadly stimulate the economy (Morganti, 2010). 
Among nanomaterials for cosmetic use, biopolymeric nanoparticles are of particular 
interest because they enable high drug loading and release efficiency and controlled size 
distribution (Reis et al., 2006), and since they are composed of biocompatible and 
biodegradable polymers they also possess improved safety and stability in biological fluids, 
(Mohanraj et al., 2006;Nagavarma et al., 2012). 
Silk Fibroin (SF) protein is a Food and Drug Administration (FDA) approved natural 
biopolymer that has been extensively studied for various applications (Cao, Y et al., 2009). 
SF impressive mechanical properties, good biocompatibility, biodegradability and 
bioresorbability are the main reasons for this interest (Cao, Y et al., 2009), leading to the 
development of SF innovative based-materials, such as films, sponges, hydrogels, fibers, 
tubes and micro or nanoparticles (Rockwood et al., 2011). 
Recently, SF based-particles have been proposed as controlled drug delivery systems, 
(Wang, X et al., 2007;Sharma et al., 2011). This SF nanoparticles can be prepared by 
emulsification, for example (Lovelyn et al., 2011). These nanoemulsions are formed by 
mixing of an organic phase (oil) with an aqueous phase (water) (Sundar et al., 2010), using 
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high-energy methods, like ultrasonication and high pressure homogenization (HPH) 
(Lovelyn et al., 2011). 
Having in consideration that some studies have also suggested that release of organic 
oils from protein particles can promote inhibition of high levels of Human Neutrophil 
Elastase (HNE) (Silva et al., 2012), we suggested to combine this ability with the excellent 
SF properties in nanoparticles for further incorporation with a synthetic HNE inhibitor, 
sivelestat. 
HNE belongs to serine proteinase of the chymotrypsin family (Korkmaz et al., 2008), 
which is mostly stored in granules of azurophilic neutrophils (Weitz et al., 1986;Woodman 
et al., 1993). In inflammatory responses, HNE is expressed by neutrophils leading to 
disruption of collagen and elastin fibers, and consequently damaging ECM in dermis 
(Imokawa, 2008;Rijken, 2011;Takeuchi et al., 2010).  
Therefore, topical application of the new developed nanodevice will allow better 
control of HNE-induced cell damage and skin diseases, as an anti-wrinkling agent, since HNE 
is involved in wrinkle formation due to repeated UV irradiation and mild inflammation 
(Imokawa, 2008;Takeuchi et al., 2010). 
Throughout this project it was intended to produce silk fibroin nanoparticles (SF-
NPs) for transdermal delivery by two high-energy emulsification methods, ultrasonication 
and high pressure homogenization (HPH). As a first stage on the various conditions were 
tested, silk fibroin concentration, oil-in-water ratio and homogenization cycles, using n-
dodecane as oil phase. 
After optimization, various surfactants were added to the best formulations in order 
to compare their stabilization effect. Then, incorporation of the HNE inhibitor sivelestat in 
the SF-NPs was assed, however before sivelestat incorporation studies, a model-drug 
compound was first studied, orange IV, to establish a drug-model of incorporation and 
release. 
Finally, the structure of the formulated nanoparticles was studied by FTIR-ATR, to 
compare secondary structure and content of Ⱦ-sheets. 
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2. Overview 
 
This dissertation research is organized in four parts (excluding references and 
annexes) containing seven chapters. The contents of each part and chapter are synthetized 
below: 
 
 
First part – General introduction 
 
Chapter I: Introduction – In this chapter, the dissertation work is summarized and 
the thesis contents are introduced, in order to facilitate reading. 
 
Chapter II: Literature Review - This chapter intends to review all the knowledge 
needed for the development and understanding of this work which goal is to develop silk 
fibroin nanoparticles for inhibition of wrinkle formation in photoaging by transdermal 
route. In other words, presents comprehensive overview of nanoparticles for transdermal 
delivery, silk fibroin protein as a polymeric protein used in biomaterials and finally, wrinkle 
formation mechanism involving Human Neutrophil Elastase (HNE) and the inhibition 
mechanism associated. 
 
 
 
Second part – Materials and Methods 
 
Chapter III: Materials and Methods – In this chapter, the materials and the 
experimental procedures used along the work are described in detail. This enables 
understanding of how the experiments were carried, allowing others to repeat. 
 
 
 
Third part – Results and Discussion 
 
Chapter IV: Optimization Production Process of SF-NPs by High-energy 
Emulsification – In this chapter, silk fibroin nanoparticles (SF-NPs) production is 
optimized according to two high-energy emulsification methods (ultrasonication and high 
pressure homogenization). The results on this chapter, besides providing knowledge of how 
this two emulsification systems work, it also indicates the best parameters and 
formulations, providing a guideline for further silk fibroin nanoparticles production. 
 
Chapter V: Incorporation in SF-NPs for Transdermal Delivery – In this chapter, 
first, incorporation studies of various stabilizers in the NPs formulations were evaluated in 
order to study their potential in silk fibroin nanoparticles stabilization over time. Then, 
incorporation of a model-drug compound, orange IV, and with the HNE inhibitor, sivelestat, 
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in optimized silk fibroin nanoparticles was assessed, this enables understanding of the drug 
release profile and HNE inhibition effect of this developed silk fibroin nanoparticles. This 
chapter results will allow final design of the silk fibroin nanoparticles, namely their 
stabilization and application as an anti-wrinkling agent. 
 
Chapter VI: Structure Analysis of SF-NPs by FTIR Spectroscopy– This chapter 
reports the silk fibroin structure changes that occur in emulsification using high pressure 
homogenization, providing a better understanding of this method. 
 
 
Fourth part – Conclusion 
Chapter VII. General Conclusions and Future Perspectives – In this chapter, the 
final remarks of this research work and the future work than can follow are presented. 
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Chapter II. Literature Review 
 
1. Nanoparticles as Drug Delivery Systems 
 
Nanotechnology concept first emerge in Taniguch article, where it was described as ǲintegrated manufacturing technologies and machine systems which provide ultra-
precision machining capacity in the order of ͳ nanometreǳ (Taniguch, 1983); and interest in this ǲextreme technologyǳ has been growing ever since (Park, 2007), especially for drug 
delivery systems (DDS) (Reis et al., 2006). Nanotechnology definition has evolved, and 
currently is defined as research and development in atomic, molecular and macromolecular 
scales, with the purpose to create and study structures and/or devices at a nanometre scale 
(Sundar et al., 2010). The considered range for this technology generated some discussion 
in the scientific community, some authors consider 10-1000nm range (Soppimath et al., 
2001), others consider below 100 nm (De Jong et al., 2008), still the exact range is not very 
relevant. 
Studies have reported that nano dimensions present advantages comparing to other 
technologies, such as high drug loading and release efficiency and controlled size 
distribution (Reis et al., 2006). Nanoparticles are, by definition, solid drug carriers at a nano 
range (Reis et al., 2006). For drug delivery (DD) purposes, the drug can be entrapped, 
encapsulated or attached to the nanoparticle, namely nanocapsules or nanospheres, 
according to the production method (Soppimath et al., 2001). Briefly, nanocapsules consist 
in vesicular systems with the drug confined in a cavity surrounded by a membrane; while 
nanospheres are a matrix system in which the drug may be absorbed at the sphere surface 
or encapsulated (Mohanraj et al., 2006;Reis et al., 2006). Each type of nanoparticle is 
represented in Figure II.1 A and B, respectively.  
 
 
 
Figure II.1. Schematic representation of nanoparticles: (A) Nanospheres and (B) Nanocapsules, adapted from 
Orive et al., 2009. Legend: Darker spheres represent the drug molecules. 
 
 
A         B 
CHAPTER II. LITERATURE REVIEW 
 
 
10 
For nanoparticle (NP) design for drug delivery is important to control particle size, 
surface properties and drug loading and release profile (Mohanraj et al., 2006). This 
characteristics will define the drug-action on the desired target at a therapeutically rate and 
dose (Mohanraj et al., 2006). Summarizing, the NPs as DDS must be safe, biocompatible, 
non-toxic, stable and with optimal life-span to allow drug targeting and delivery at a 
therapeutic need (De Jong et al., 2008). 
In order to obtain biocompatible and safe nanoparticles for drug delivery, 
nanoparticles production method cannot involve toxic reagents or if so, these should be 
easily removed from the final product without affecting its properties (Reis et al., 2006). In 
addition, the production method must be simple and cheap to allow production at large 
quantities, i.e. scale-up production (Park, 2007), reproducible and efficient (Reis et al., 
2006). 
Nanoparticles can be produced from various materials, including proteins, 
polysaccharides and polymers (Sundar et al., 2010). In fact, the NPs material defines their 
final characteristics, namely size, morphology, surface charge, permeability, life-span, 
toxicity, drug loading and release efficiency, among others (De Jong et al., 2008;Mohanraj et 
al., 2006). 
 
 
1.1. Biopolymeric Nanoparticles 
 
Polymeric nanoparticles, as the name suggests, are nanoparticles produced from 
polymers, and these are separated in two categories, synthetic polymers and natural 
polymers, whereas this last one involves polymeric proteins and polysaccharides (Sharma 
et al., 2011). Initially, synthetic polymers received more attention than natural polymers, 
because polymers of natural origin often require processing treatment, which could lead to 
denaturation, and additionally, to different purity levels (Hans et al., 2002). However, 
synthetic polymeric NPs started to generate some concerns relating to toxicological 
problems due to non-biodegradable polymers, preventing their use as DDS (Sundar et al., 
2010).  
To overcome this problem, DD nanoparticles started to be prepared from 
biocompatible and biodegradable polymers (Nagavarma et al., 2012). These drug carriers 
feature numerous advantages over the existing systems (Mohanraj et al., 2006), such as 
improved safety, drug release efficiency and stability in biological fluids (Mohanraj et al., 
2006;Nagavarma et al., 2012). However, these biopolymeric nanoparticles may present 
some instability in liquid and dry form, since smaller size and large surface area particles 
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can react and aggregate, but this limitation can be overcome by polymers choice and 
production process optimization (Mohanraj et al., 2006). 
Examples of potential DD synthetic biopolymers is poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA) and poly(lactide-co-glycolic acid) (PLGA) (Hans et al., 2002), but 
synthetic polymers present difficulty in stabilize the drug within the particle and protect 
the particle against enzymatic degradation due to their hydrophobic nature, wherein 
natural polymers like proteins are mainly hydrophilic (Sundar et al., 2010). Hence, natural 
occurring materials showed to be more promising DDS, where the most widely used 
polymeric proteins are albumin, gelatin, collagen and silk fibroin, and polymeric 
polysaccharide are alginate and chitosan (Sundar et al., 2010). 
 
Finally, is important to highlight that all the DDS characteristics, such size, 
morphology and even drug release profile, are defined along its production process, from 
the material used to the methodologies used (De Jong et al., 2008;Mohanraj et al., 2006). 
 
 
1.1.1. Biopolymeric Nanoparticles production methodologies 
 
The most commonly used methods for protein or/and polysaccharide based-
nanoparticles are Coacervation/Desolvation and Emulsification (Sundar et al., 2010;Pathak 
et al., 2009). 
 
Coacervation/Desolvation method uses the differential solubility of proteins in 
solvents to produce the nanoparticles, and the desired characteristics are obtained by 
controlling the processing variables such as solvent polarity, pH, ionic strength and/or 
presence of electrolytes (Pathak et al., 2009). In coacervation, the protein solubility is 
reduced, using antisolvents like acetone or ethanol, leading to a phase separation (Pathak 
et al., 2009). Then, a desolvating agent is added causing the protein to change its tertiary 
structure and forming protein clumps, and finally these clumps are cross-linked with a 
chemical substance, for example glutaraldehyde or glyoxal, producing the final 
nanoparticles directly in aqueous solution (Pathak et al., 2009). 
The chemical substances used in this process are toxic, so its removal is normally 
achieved by centrifugation or redispersion (Sundar et al., 2010), but these purification 
process leads to low yields (Reis et al., 2006). Still, since this process does not use high 
temperatures, is widely used to produce nanoparticles for delivery heat-sensitive drugs 
(Reis et al., 2006). 
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Emulsification method involves formation of an emulsion, in this case in particular, a 
nanoemulsion (Sundar et al., 2010). An emulsion is defined as colloidal dispersion of liquid 
droplets in another immiscible liquid phase (Mason et al., 2006;Mason et al., 2006), 
produced by extreme mixing of an organic phase (oil) with an aqueous phase (water) 
(Sundar et al., 2010). Briefly, the resulting droplets occur due to hydrophobicity differences 
between both phases, wherein attraction and repulsion of these two phases leads to an 
interfacial tension where the oil and water connect (Mason et al., 2006;Mason et al., 2006). 
The emulsification process is summarized in Figure II.2. 
 
Figure II.2. Schematic representation of emulsification process, adapted from Mason et al., 2006. (A) Initially 
two immiscible liquids, oil and water, are two separated phases; (B) wherein surfactant can be added to improve 
formulation stability. (C) Then, applying high-energy, like shear, causes oil to break up into droplets (which are 
coated with the surfactant), (D) resulting in an emulsion.  
 
Emulsions are generally classified according to its morphology, whereas the oil or 
water are continuous phase or dispersed phase (Mason et al., 2006;Mason et al., 2006). 
When continuous phase and dispersed phase are water and oil, respectively, the emulsion 
is termed by direct, water-based or oil-in-water (o/w) emulsions (Mason et al., 2006;Mason 
et al., 2006). When water droplets are dispersed in oil, the emulsion is called by inverse, oil-
based or water-in-oil (w/o), i.e. when continuous phase and dispersed phase are oil and 
water, respectively (Mason et al., 2006;Mason et al., 2006). Additionally, exists double-
emulsions, for example water-oil-water, (w/o/w), and multiple emulsions, such as water-
oil-water-oil (w/o/w/o) (Su, 2008). 
The nanoemulsion processes are non-equilibrium and non-spontaneous systems, 
therefore its production requires a large input of energy (Lovelyn et al., 2011) or addiction 
of surfactants, which reduce significantly the interfacial tension (Mason et al., 2006;Mason 
et al., 2006). 
Consequently, emulsification can be achieved using high-energy methods, where 
intensely disruptive forces, created by specific mechanical devices, break the oil and water 
phases leading to nanosized droplets (Lovelyn et al., 2011). Those high-energy mechanical 
devices can be ultrasonication, high pressure homogenization (HPH) and microfluidization 
(Lovelyn et al., 2011). 
A  B             C          D 
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In more detail, when pre-emulsion (oil and water separated phases) are irradiated 
with ultrasound bubbles are created, due to the alternating expansive and compressive 
acoustic waves (Bang et al., 2010). This process is termed by cavitation, wherein these 
bubbles can accumulate ultrasonic energy, and implode to release the stored energy, 
leading to nanoparticles (Bang et al., 2010). Additionally, ultrasonic irradiation generated 
free radicals, namely reactive oxygen species (Hofmann et al.), still NPs production by this 
method is FDA approved and findings have suggested that this process does not lead to 
protein degradation or denaturation (Bang et al., 2010). As disadvantage, this mechanism 
is mainly used at laboratory scale, so scale-up is difficult (Lovelyn et al., 2011). 
Regarding HPH, in this high-energy method more disruptive forces are involved, such 
as hydraulic shear, intense turbulence and cavitation, which is common to ultrasound 
(Lovelyn et al., 2011). In HPH, the pre-emulsion is pressed at high pressure through a 
narrow slit, creating the air bubbles (Grebler et al., 2010). When the liquid emerges from 
the slit, the bubbles implode and collide, forcing oil to break up in emulsion drops (Grebler 
et al., 2010). These circuit is repeated in numerous cycles, decreasing the droplets size into 
to nano range droplets, and consequently forming the nanoparticles (Grebler et al., 2010). 
Finally, microfluidizer is an improved mechanism similar to HPH (Lovelyn et al., 
2011). It uses a high-pressure positive displacement pump which forces the pre-emulsion 
to pass through various small channels, called by microchannels (Lovelyn et al., 2011). 
Following, the bulk emulsion is filtered through a nitrogen filter to remove the large 
droplets, resulting in more stable and uniform nanoemulsions (Lovelyn et al., 2011). 
 
Surfactants are amphiphilic surface-active molecules, highly soluble in one of the 
phase, that act as stabilizers of the nanoformulations (Mason et al., 2006;Mason et al., 2006). 
In fact, presence of surfactants prevents the system to revert to a lower energy 
configuration at thermodynamic equilibrium (Mason et al., 2006;Mason et al., 2006). The 
surfactants are classified according to hydrophilic lipophilic balance (HLB), which defines 
their relative solubility in aqueous and oil liquid phases (Mason et al., 2006;Mason et al., 
2006). Surfactants with high and low values of HLB indicate that is more soluble in water 
and oil, respectively (Su, 2008). Is important to note that HLB values are affected by 
different parameters like temperature, composition, among others (Lovelyn et al., 2011). 
The only disadvantage of this method is the need of an organic phase that has to be 
removed because it may cause toxic problems (Sundar et al., 2010). Still most organic 
solvent can be removed by simple evaporation (Sundar et al., 2010), and may affect the 
produced nanoparticle characteristics (Mason et al., 2006;Mason et al., 2006). 
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2. Transdermal Delivery 
 
Drug delivery through the skin to the systemic circulation is very useful for several 
clinical conditions (Lovelyn et al., 2011), and has been used as an alternative to oral, 
intravascular, subcutaneous and transmucosal routes (Kumar et al., 2010). 
Comparing to the conventional modes of drug administration, transdermal delivery 
avoids gastrointestinal absorption preventing enzymatic and pH inactivation of the DDS, 
therefore reduces the dosage (Pankaj et al., 2011), preventing the potential side effects 
(Kumar et al., 2010). Besides, steady absorption of drug over hours or days is rather 
desirable than the blood level spikes produced by oral dosage forms (Kumar et al., 2010). 
Additionally, transdermal DDS is also more convenient to administer drugs and 
administration interruption is more flexible, being more comfortable, painless and simple 
to the patient (Kumar et al., 2010). 
Conversely, it possesses some disadvantages including, possible local irritation in 
application site and inflammatory responses can be trigged, like erythema, itching and local 
edema, and production is more expensive than other alternative routes for DDS (Kumar et 
al., 2010). 
 
 
 
Transdermal drug delivery allows medicines to be delivered via the skin over an 
extended period of time, at a predetermined and maintained rate of an effective drug 
concentration (Pankaj et al., 2011). However, the transdermal route presents a major 
barrier within the skin, the stratum corneum (SC) (Kumar et al., 2010), which is localized in 
the top layer of the dermis, within the bilayer lipid matrix (Prow et al., 2011). 
 
The following figure II.3 represents various epidermal 
layers in a cross-section image of skin, edited by Mikael 
Häggström, from Wbensmith work and published in 
Wikimedia in 2010. Being the most relevant in this work the 
stratum corneum. 
 
Figure II.3. Cross-section of the skin with the epidermal layers 
represented, image adapted from Häggström, 2010. The keratynocytes 
maturity and differentiation increases with the deep of the skin. From 
exterior to dermis, the epidermal layers are stratum corneum (cornified 
layer), stratum lucidum (translucent layer), stratum granulosum (granular 
layer), stratum spinosum (spinous layer) and stratum basale (basal or 
germinal layer) (Weedon, 2002). 
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The stratum corneum (SC) consists of a 10-20 µm protect layer (Buzea et al., 2007) of 
flattened and anuclear dead cells, composed with keratin fibers (corneocytes) (Prow et al., 
2011). To be noted, these dead cells were fragments of once active dividing epidermal cells 
(Kumar et al., 2010) and the corneocytes integrity is maintained by corneodesmosomes 
(Prow et al., 2011). The SC arrangement is often called by ǲbrick and mortarǳ, in this analogy 
corneodesmosomes are the mortar and the corneocytes are the bricks (Prow et al., 2011). 
 
The drug delivery through the SC can occur by passive diffusion and/or by three 
possible routes, intercellular, transcellular and appendageal (Prow et al., 2011). Initially, 
delivery across SC of polar and non-polar solutes were thought to occur via transcellular 
and intercellular route, respectively (Prow et al., 2011). But studies showed that most 
solutes diffuse through intercellular pathway, in fact between this two, intercellular route 
is considered the most favourable (Prow et al., 2011).  
Even so, small molecules can cross freely between the intercellular spaces, the 
macromolecules or larger particles are physically constrained, indeed the diffusion rated 
through this route depend on molecular weight, the capability to establish interactions and 
forces, solubility and lipophilicity of the crossing material (Prow et al., 2011). 
Hence, the appendageal route is considered as a realistic alternative, where the 
crossing is focused in the hair follicles, called by transfollicular route, or through sweat 
glands (Prow et al., 2011). Since the hair follicles are deeply extended in the skin and 
connected to a capillary blood supply, the diffusion out of the follicle of the DDS through the 
skin is possible (Prow et al., 2011). In fact, Toll and co-workers studies shown that spherical 
particles with 750nm - 6µm of diameter were able to penetrate selectively through hair 
follicles at 2.4 mm of depth (Toll et al., 2004;Buzea et al., 2007). 
Furthermore, if the skin is damaged and the normal barrier disrupted, entry of DDS 
through SC may be significantly increased (Patel et al., 2011), such as Monteiro-Riviere 
findings have suggested that larger particles of 500 nm – 7 µm of diameter can penetrate 
broken skin (Monteiro-Riviere et al., 2005;Buzea et al., 2007). 
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2.1. Nanoparticles in cosmetic applications 
 
Currently, engineered nanosystems are applied in several areas, including cosmetic 
industry (Morganti, 2010). Several cosmetics and personal care products use nanomaterials 
(Buzea et al., 2007;Morganti, 2010), which are mostly produced by nanoemulsion, since it 
produces transparent and pleasant products to touch (Patel et al., 2011). In fact, 
nanoemulsions are used in deodorants, sunscreens, shampoos and skin and hair care 
products, because nanoemulsions increase stabilization of the nanomaterials and are more 
suitable for drug delivery (Grebler et al., 2010). 
Nanomaterials are capable to deeply penetrate the skin with improved efficiency than 
the previous cosmetics (Buzea et al., 2007), allowing nanoparticles encapsulated 
nanoparticles with active cosmetics to be delivered through the skin (Morganti, 2010). 
Cosmetic products are used to enhance beauty, magnificence and attractiveness of the 
skin and protect it against exogenous and endogenous harmful and damaging agents 
(Morganti, 2010;Roy et al., 2012). 
Ever since, use of nanomaterials and nanoparticles in cosmetic industry has able 
fragrances to last longer, sunscreens to be more effective allowing better UV protection 
(Patel et al., 2011), development of anti-ageing creams by concealing wrinkles with 
nanoparticles (Buzea et al., 2007), maintenance of hair properties, among others (Morganti, 
2010;Patel et al., 2011). 
In conclusion, cosmetic products are the best solution to develop attractive external 
appearance of the skin and reduce or prevent skin disorders, such as hyper pigmentation, 
aging, wrinkles, rough texture, and others (Morganti, 2010;Roy et al., 2012). 
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3. Silk Fibroin, a biopolymeric protein 
 
Silk fibroin (SF) is a natural protein polymer, produced by some lepidoptera larvae, 
like silkworms and spiders (Altman et al., 2003). Depending on its source, the silk 
composition, structure and properties differ extensively, according to its biological function 
and need (Altman et al., 2003). These fibers are involved in cocoon formation for protection 
of eggs and larvae, web formation and support for spiders, and in insect traps for predation 
(Kearns et al., 2008;Nagarkar, 2010). 
One of the most characterized silks comes from the silkworm Bombyx mori due to its 
long history of domestication (Kaplan, 1994) and use in textile fibers and in medicine, as 
sutures and artificial ligaments (Sah et al., 2010). Due to its biocompatible and mechanical 
properties, its use has been increasing dramatically in biotechnology and biomedical areas 
(Altman et al., 2003). 
 
Native Silk fiber from B. mori consists in two different proteins: sericin, a glue-like 
protein that binds the structural fibrous protein, fibroin, into fibers (Kaplan, 1994). This Silk 
fibroin as a polymer consists in a repetitive primary polypeptide sequences of amino acids 
(-Gly-Ala-Gly-Ala-Gly-Ser-), that leads to antiparallel Ⱦ-sheets (Cao, Z et al., 2007) due to the 
hydrophobic domain predominance as result of homogeneity in secondary structure 
(Vepari et al., 2007).  
B. mori silk secreted into the posterior silk gland is composed of a three protein 
components: Heavy (H) chain of 350 kDa, Light (L) chain of 25 kDa and Glycoprotein P25 of 
30 kDa, in a molar ratio of 6:6:1, respectively (Mondal et al., 2007). The light chain that is 
linked to the heavy chain by a single disulphide bond has 262 amino acid (a.a.) residues and 
a nonrepetitive sequence (Zhou et al., 2001). While the heavy chain has 5263 residues and 
is composed of 45.9% of glycine (Gly), 30.3% of alanine (Ala), 12.1% of serine (Ser), 5.3% 
of tyrosine (Tyr), 1.8% of valine (Val) and 4.7% of the other 15 a.a. types (Zhou et al., 2001). 
Besides the heavy chain has a low-complexity repetitive sequence, in fact most of the 
sequence forms 2377 repetitions of a Gly-X dipeptide motif, with X being Ala, Ser, Tyr and 
Val (Zhou et al., 2001). 
For better elucidation, the quantitative amino acid composition for silk fibroin, 
published in Vasconcelos et al., 2008, is presented in a table (Table Annex.1) in Annex I. 
 
Since 1953 there is some discrepancy regarding the silk fibroin molecular weight 
(MW), in fact various studies present large differences on the SF MW values, being this 
differences influenced by the silk fibroin process (Hyde et al., 1962). The most accepted SF 
MW value is 391 367 Da (Zhou et al., 2000). 
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A number of B. mori silk fibroin crystalline structures have been reported, the 
glandular state (Silk I), the crystalline silk structure (Silk II) and an air/water interface 
orientation (Silk III) (Vepari et al., 2007). 
The structure of Silk I is the water-soluble state (Vepari et al., 2007) that ordinarily 
occurs in the silkworm glands (Malay, 2005) and it contains random-coil and amorphous 
regions (Cao, Y et al., 2009). Also is unstable to mechanical deformation (Kaplan, 1994) 
since upon heat exposure or physical spinning converts to antiparallel Ⱦ-sheet, the Silk II 
structure (Vepari et al., 2007). In addition, Iizuka et al. studies have shown that Silk II 
structure can also dissolve without precipitation in mixed solvents of water and methanol 
or dioxane (Iizuka et al., 1968;Vepari et al., 2007).  
 
Regarding the Ⱦ-sheet silk structure (Silk II), Takahashi et al. proposed an antiparallel 
hydrogen bonded sheets, i.e. adjacent strands oriented in opposite directions, with one side 
occupied with hydrogen side chains from glycines and the other with methyl side chains 
from alanines (Kaplan, 1994;Vepari et al., 2007;Takeuchi et al., 2010). As mentioned above, 
this crystalline conformation establishes strong intermolecular hydrogen bonding and van 
der Waals forces that lead to a thermodynamically stable structure, preventing the 
separation of molecules (Kaplan, 1994;Malay, 2005) and the water dissolution, including in 
mild acid and alkaline conditions, and several chaotropes (disruption agents, they increase 
the entropy and interfere with the protein interactions) (Vepari et al., 2007). 
This crystalline structure is schematized in Figure II.4, where grey dashed represents 
the hydrogen bounds and grey line shows stabilization between C-terminal and N-terminal 
of two SF chains in an antiparallel direction, which forms the secondary structure Ⱦ-turns 
and consequently the Ⱦ-sheets. This Ⱦ-sheets and Ⱦ-turns in Bombyx mori SF structure are 
highlighted in Figure II.5 (yellow and violet colours, respectively). To be noted the deduced 
molecular structure of silk fibroin presented in Figure II.5 was obtained by expression in 
Escherichia coli. 
 
Figure II.4. Schematic representation of Ⱦ-sheet antiparallel structure of silk fibroin protein, stabilized with 
hydrogen and van der Waals bonds. Legend: grey dashed line represents intra-chain hydrogen bonds and grey 
line represents stabilization of C and N-terminal between two SF chains. 
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Figure II.5. Molecular representation of N-terminal domain of Bombyx mori silk fibroin secondary structure, 
expressed in Escherichia coli. Modulation performed in jmol and stored in protein data bank (PDB) by PDB 
identification (PDB ID) of 3UA0. Legend: yellow represents Ⱦ-strands; violet represents Ⱦ-turns; and white 
represents none assigned or defined structure. 
 
Finally, the crystal Silk III structure involves a hexagonal arrangement of silk 
molecules in a threefold helical chain conformation caused by the serine and alanine 
residues separation (Valluzzi et al., 1999). This structure was first observed in films taken 
from the air-water interface of aqueous fibroin solutions in Valluzzi et al. previous 
experiments (Valluzzi et al., 1999). 
The silk fibers stability and Ⱦ-sheets structure provides SF unique strength, toughness 
and elasticity, which is much desired in biomaterials industry (Altman et al., 2003). In fact, 
currently silk fibroin protein has been extendedly applied in films, membranes, sponges, 
three-dimensional scaffolds, hydrogels, powders, electrospun fibers and microspheres 
(Kundu et al., 2010;Cao, Y et al., 2009). Besides, the crystallinity levels of silk fibroin and 
morphology can be applied in drug release control (Mandal, BB et al., 2009). 
 
 
3.1. Silk Fibroin processing 
 
For many years, silk has been used as sutures in medicine in spite that this material 
had to be treated with waxes or silicone, since untreated silk was considered a potential 
allergen, leading to type I allergic responses (immediate hypersensitivity) (Altman et al., 
2003). Findings of Wen and co-workers have reported that sericin protein was responsible 
for the allergenic responses, and when removed from silk, leaving only silk fibroin, the 
material was considered safe (Wen et al., 1990;Altman et al., 2003). 
Therefore, in order to use silk fibroin protein as a biomaterial, silkworm silk requires 
removal of contaminating sericin to avoid biocompatibility problems and then, dissolution 
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of structure Silk II of silk fibroin, which contains Ⱦ-sheets, in aqueous solution since is 
insoluble in water. 
Sericin removal is obtained by alkali salt heat treatment, called degumming process 
(Malay, 2005). Briefly, the original silk (Bombyx mori cocoons) is dissolved in Na2CO3 or 
NaHCO3 solution at 100 °C, resulting in cotton-like fluffy mass of sericin-free silk, i.e. silk 
fibroin fibers (Wray et al., 2011;Sah et al., 2010). 
The degumming process affects the silk fibroin produced material, namely 
mechanical properties like elasticity, molecular weight and cell viability (Wray et al., 2011). 
Wherein mechanical changes are caused by disruption of hydrogen and van der Waals 
bonds (Wray et al., 2011) but these changes were considered insignificant when compared 
to dissolution process of the degummed silk (Kearns et al., 2008); and molecular weight and 
cell viability decreases when increasing degumming time because the treatment can lead to 
degradation of silk fibroin into lower molecular weight fragments, that can affect cell 
function (Wray et al., 2011). Therefore the process conditions needs to be controlled to 
ensure complete removal of sericin, without degradation of silk fibroin, in which the 
optimized process involves boiling Bombyx mori cocoons in 0.05-0.01M of sodium 
carbonate (Na2CO3) for 20-30 minutes, which maximal concentration of cocoons to total 
solution volume, w/v (g/L), is 5:1 (Sah et al., 2010;Wray et al., 2011).  
 
Following, the degummed material is dissolved in an heated organic-aqueous 
concentrated solution of salts, such as calcium chloride (CaCl2) or lithium bromide (LiBr), 
(Sah et al., 2010) since SF protein is destabilized and its solubility is increased in high ionic-
strength of chaotropic salts (Sah et al., 2010). In general, this process is performed with 9-
9.3M concentration of LiBr at 60-70°C, until complete dissolution, 3-5 hours (Sah et al., 
2010). Finally, dissolved silk fibroin is dialyzed against double distilled water to prepare an 
aqueous silk fibroin solution without salts (Wray et al., 2011), called regenerated silk fibroin 
(RSF). 
 
For a better elucidation, silk fibroin processing is schematized in Figure II.6. 
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Figure II.6. Schematic representation of silk fibroin extraction process, images adapted from Malay, 2005 and 
(Rockwood et al., 2011). Legend: (A) original silk material of silkworm Bombyx mori cocoons, (B) degumming 
process, (C) dissolution of degummed silk in LiBr, (D) filtration process, (E). Dialysis process, resulting in RSF 
solution. 
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3.2. Silk Fibroin as a biomaterial 
 
Silk Fibroin protein as a natural biopolymer presents advantages over synthetic 
polymers, including favourable mechanical properties, good biocompatibility, 
biodegradability and bioresorbability (Cao, Y et al., 2009), which makes it an environment-
friendly solution (Malay, 2005), suitable for biomedical applications. 
 
As already mentioned, silk fibroin is a safe material since it does not triggers 
inflammatory or toxic responses in vitro and in vivo, as long as sericin protein is removed in 
the degumming process. In fact, this material is approved by FDA (Cao, Y et al., 2009). 
Additionally it possesses high permeability to oxygen and water-vapour, as demonstrated 
in Minoura et al. studies of silk fibroin membranes, which is promising in applying silk 
fibroin as skin dressings, like wound dressing artificial skin, contact lenses or even as 
scaffolds such as artificial corneas or bone (Malay, 2005). 
Indeed, SF process is very versatile, making it possible to produce silk fibroin films, 
scaffolds, delivery particles or hydrogels (Rockwood et al., 2011). In which the desired 
characteristics can be obtained by simply change the processing conditions or by additional 
treatment (Malay, 2005;Cao, Y et al., 2009). 
In addition, silk fibroin protein is very environment stable when comparing to 
globular proteins (Vepari et al., 2007) because hydrogen bonds, high hydrophobic 
proportion and crystallinity features enhance its stability (Altman et al., 2003). 
 
Another important property in biomaterials is its biodegradation because the 
material must maintain its characteristics till reach the target and then be degraded by 
organism, therefore should have acceptable life-span (Cao, Y et al., 2009). 
Silk Fibroin is defined as non-degradable by United States Pharmacopeia however 
this classification is set only for 60 days, and SF is degradable after this time, actually 
Ethicon, Inc. in patent US 4014973 (Darrell, 1973) claims that SF fibers maintain tensile 
strength for one year (Altman et al., 2003). 
SF degradation results of proteolytic enzymes mediated by a foreign body response 
(Cao, Y et al., 2009), where studies report protease as major responsible (Kearns et al., 
2008). Since low molecular weight and non-compact structures are more easily hydrolysed 
by proteases, silk fibroin biomaterials should be designed according to the desired 
degradation rate (Cao, Y et al., 2009), and this can be accomplished by changing crystal 
content, porosity including pore size and molecular weight distribution (Vepari et al., 2007). 
Additionally, implantation site, size, geometry and surface properties also influence 
degradation behaviour (Altman et al., 2003). 
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3.2.1. Silk Fibroin based-materials 
 
The silk fibroin protein can be further processed into different materials, films, 
sponges, hydrogels, fibers, tubes and micro or nanoparticles (Rockwood et al., 2011;Sharma 
et al., 2011). 
 
Currently, silk fibroin has been proposed as a material for tissue engineering, since its 
mechanical properties, biocompatibility and biodegradability, would enable its use in vivo 
and the degradation rate would be similar to the new tissue growth (Yang et al., 2012). In 
fact, Inouye et al. findings in use of silk fibroin film in several culturing animal cells as a 
substratum, concluded that silk fibroin are able to support cell attachment, physiological 
morphology and growth (Altman et al., 2003). In addition, Altman, 2003 studies concluded 
that SF films induced bone tissue growth in vitro and Sugihara, 2000 studies shown that 
they heal full thickness skin wounds in rats faster than traditional porcine-based wound 
dressings (Vasconcelos et al., 2012;Sugihara et al., 2000;Altman et al., 2003). Besides, SF 
films can also be applied for DD by encapsulating bioactive molecules within the film 
(Mandal, BB et al., 2009). 
 
SF use as three-dimensional (3D) porous scaffolds provides a microenvironment for 
cell attachment, proliferation, differentiations and tissue neogenesis (Zhang, Q et al., 2009), 
and have been used in a number of studies for connective tissue regeneration (Vepari et al., 
2007). As reported in Meinel et al., 2005, this structures have been reported to regenerate 
and heal femur deficiencies in rats (Vepari et al., 2007). 
 
Hydrogels, by definition, are 3D polymer networks non-dissolving and physically 
durable to swelling in aqueous solutions (Vepari et al., 2007). This structures when 
constituted by a biocompatible material, like silk fibroin, can be applied in biomedical 
applications, for example in soft tissue regeneration (Rockwood et al., 2011) and drug 
delivery for wound healing. 
SF hydrogels structure is mainly dependent on Ⱦ-sheets content (Vepari et al., 2007), 
indeed during gelation process, increase of hydrophobic interactions, van der Waals forces 
and hydrogen bonds, lead to structural transition of random-coil to Ⱦ-sheets (Zhang, Q et al., 
2009). To better understand, SF hydrogel formation is further detailed in Annex II, in 
Annexes section. 
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Silk fibroin fibers possess the unique ability to be weaved into a wipe-rope geometry, 
and since it design can be controlled, is possible to achieve the desired final mechanical 
properties (Altman et al., 2003). Their high functionality, surface area and porosity; and 
their ability to improve cell migration and proliferation, also allows its use in tissue 
regeneration and as DDS (Zhang, X et al., 2011). In effect, SF wipe-rope with mechanical 
properties similar to the human anterior cruciate ligament (ACL) are used as biomaterial 
replacements for ligaments in tissue regeneration (Vepari et al., 2007). 
 
Currently, silk fibroin based-particles have been proposed as controlled drug release 
and delivery system, since is a biocompatible material and presents a well-defined model 
for degradation and drug release (Wang, X et al., 2007) due to the control of the Ⱦ-sheets 
formation (Hofmann et al., 2006). 
The micro and nanospheres have been produced by various methods, like 
emulsification (already discussed in section II. 1.1.1) spray-drying, lipid vesicles, and others. 
In detail, production using spray-drying method enables formation of 100 µm particles, yet 
in this process high temperatures are involved, limiting its use for SF drug release (Wang, X 
et al., 2007). In addition, preparation of SF micro and nanoparticles under mild processing 
conditions recommends lipid vesicles methodology, which uses lipid templates to shape the 
microspheres however it uses toxic compounds, such as methanol (Wang, X et al., 2007).  
 
Interestingly, Silk has been developed as a microneedles system (500 µm of height 
and 10 µm of tip radii) to deliver precise amounts of drugs over time by Biomedical 
Engineering department of Tufts University (Tsioris et al., 2012). This silk-based 
microneedle system presents the following advantages: no-need of refrigeration, easy 
production process, painless, environmental-friendly material, biodegradable and 
biocompatible (Tsioris et al., 2012). 
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4. Photoaging and Wrinkle Formation 
 
Photoaging, also known as extrinsic aging, refers to skin histology alterations caused 
by ultraviolet (UV) radiation exposure (Rijken, 2011). In general, the most prominent 
characteristic of skin ageing is wrinkles formation (Imokawa, 2008), yet is also 
characterized by dryness, rough texture, loss of skin tone and deep creases (Rijken, 2011). 
 
Is important to note that tissues are not solely composed by cells, it exists extra-
cellular space, termed as extra-cellular matrix (ECM) (Satardekar et al., 2010). By definition, 
ECM surrounds connective tissue cells and is composed of glycosaminoglycans connected 
with fibrous matrix proteins like collagen, elastin and fibronectin, providing structural 
support to the tissues (Satardekar et al., 2010). 
Normal dermis skin consists in a complex network of collagen and elastic fibers that 
provide elasticity and resistance to the skin, maintaining its shape and texture (Rijken, 
2011). These fibers are connected by mucopolysaccharide gel (Weedon, 2002), and are both 
produced by fibroblast, the main cells of connective tissues (Rijken, 2011). 
Collagen fibers, which constitute ~70-80% of skin, are composed by collagen 
molecules connected in triple helices structures and responsible for skin strength and 
toughness (Rijken, 2011;Weedon, 2002). 
Elastic fibers are protein bundles localized parallel or radially to the epidermis 
composed by elastin, main component of elastic fibers (~90%) that provides skin elasticity, 
and microfibril, which includes fibrilin and glycoproteins (Rijken, 2011). Degeneration of 
these elastic fibers results in accumulation of elastotic material, mainly abnormal elastin, 
also called Actinic Elastosis when caused by solar damage (Rijken, 2011). 
 
Studies reported that loss of skin elasticity leads to wrinkle formation, which is 
induced by age and cumulative exposure to sunlight (Imokawa, 2008). The physicochemical 
and biological mechanisms involved in wrinkle formation are not entirely understood, as a 
result various mechanisms have been proposed for this process (Imokawa, 2008). In fact, 
elastotic material hypothesised to be caused by degradation of elastic fibers and/or collagen 
fibers, and/or by abnormal stimulation of fibroblasts (Rijken, 2011). Furthermore, UV 
radiation easily affects the skin, entering through different skin chromophores (like 
melanin, DNA, RNA, proteins, lipids, water, aromatic amino acids, among others) and 
leading to photochemical reactions, production of reactive species of oxygen (Hofmann et 
al.), and consequently to harmful effects and skin damage (Roy et al., 2012).  
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The most plausible mechanism suggests that cellular damage caused by UV exposure 
leads to production of basement membrane-permeable biological factors that induce 
dermal fibroblasts (Imokawa, 2008). These cells rapidly induce inflammatory responses, 
including neutrophils migration, which directly express elastases and indirectly produce 
matrix metalloproteins (MMPs), that degrade elastic and break collagen fibers, respectively 
(Imokawa, 2008;Rijken, 2011;Takeuchi et al., 2010). These mechanism is supported by 
Imokawa findings, in which they observed that: UV radiation in vivo studies significantly 
reduced elastic properties of skin, resulting in wrinkles; and in vitro studies of cultured 
human fibroblasts secreted cytokines, which stimulated elastase and leaded to wrinkle 
formation too (Imokawa, 2008). For better elucidation, the mechanism that causes aging 
and wrinkle formation disorders is represented in Figure II.7. 
Additionally, UV radiation in skin also affects antioxidation, decreasing levels of 
antioxidants and inactivating of antioxidant enzymes, and increasing markers of lipid 
peroxidation in skin, leading to other skin disorders, such as hyper pigmentation (Roy et al., 
2012). 
 
 
Figure II.7. Schematic diagram of the current hypothetical model for photoaging adapted from Imokawa, 2008, 
where UV radiation induces release of biologic factors, namely cytokines and proteolytic enzymes from 
neutrophils like elastases capable of disrupt collagen and elastin proteins of ECM in dermis. 
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Neutrophil-derivated proteolytic enzymes, like Neutrophil Elastase (NE) are also 
capable of producing ROS by the membrane-associated nicotinamide adenine dinucleotide 
phosphate (NADHP) oxidase enzyme complex (Rijken, 2011). These oxidase-derived 
oxygen metabolites, ROS, can lead to overwhelming responses that ultimately damage the 
ECM proteins, like collagen and elastin (Rijken, 2011), and consequently producing 
histochemical changes in skin, such as thickening of stratum spinosum (epidermal layer, 
deeper than SC) and flatting of dermoepidermal junction (Roy et al., 2012). 
 
To be noted, solar UV (wavelengths 100-400 nm) is classified into UVA, UVB and UVC, 
which only UVA and UVB are capable of reaching earth’s surface though UVB is mostly 
blocked by stratospheric ozone layer (Rijken, 2011). Regarding to UV skin damage, UVA 
penetrates deeply into skin than UVB and is the main inducer of ROS however UVB is more 
energetic and considered as more harmful (Rijken, 2011). 
 
4.1. Human Neutrophil Elastase 
 
Polymorphonuclear Neutrophils or Leukocytes (PMNs), the most abundant type of 
phagocyte, acts in inflammation and immune responses as protection against pathogenic 
organisms and cell(s) damage by healing or destroying tissues (Rijken, 2011). In fact, PMNs 
cells provide a primary line of defence against bacterial infection, being the first cells to 
arrive to the site of inflammation (Korkmaz et al., 2008). 
The oxidative and proteolytic potential of neutrophils enables ECM degradation 
(Wagner et al., 1999), allowing them to rapidly migrate between tissues, but also to 
participate in tissue remodelling/repair, wound healing, coagulation and fibrinolysis 
(process that prevents blood clots) (Owen et al., 1999). In spite of this capability, when 
excessive, can lead to various diseases or abnormalities (Owen et al., 1999). 
 
PMNs proteolytic depends of proteinases, which cleave peptide bonds in the central 
regions of polypeptides of proteins (Owen et al., 1999). One of the most abundant neutral 
proteinases present in PMNs is Elastase (EC 3.4.21.11) (Weitz et al., 1986). 
 
  
CHAPTER II. LITERATURE REVIEW 
 
 
28 
Human neutrophil elastase (HNE), also called Human leukocyte elastase (HLE), 
belongs to serine proteinase of the chymotrypsin family (Korkmaz et al., 2008), presenting 
a catalytically essential serine residue in the enzyme (Owen et al., 1999), which are mostly 
stored in granules of azurophilic neutrophils (Weitz et al., 1986;Woodman et al., 1993) but 
are also found in monocytes (Hajjar et al., 2010). Is extremely cationic and possess an 
isoelectric point (pI) of pH 10-11 and demonstrates optimal activity at neutral pH (pH 7-9) 
(Owen et al., 1999). 
 
Structurally, HNE is a glycoprotein composed by 218 a.a. in a single polypeptide chain 
and two asparagine-linked carbohydrate side chains and its active-site is on catalytic triad 
Asp102, His57 and Ser195 residues (Owen et al., 1999), which is separated in the primary 
structure but joined in their tertiary structure (Korkmaz et al., 2008). In the 3D HNE 
secondary structure (Figure II.8), the active-site residues are established between two fold Ⱦ-barrels domains composed by six anti-parallel Ⱦ-sheets, each, typical to all chymotrypsin-
like serine proteins (Hajjar et al., 2010;Korkmaz et al., 2008). Besides, it possesses a 
carboxyl-terminal segment disposed in Ƚ-helix (Korkmaz et al., 2008). 
 
 
Figure II.8. Ribbon representation of uncomplexed secondary structure of Human Neutrophil Elastase. Legend: 
(A) Image performed in jmol, stored in PDB with ID 3Q76, where yellow represents Ⱦ-strands; pink represents Ƚ-helix; violet represents Ⱦ-turns; and white does not represents any defined structure; (B) Image adapted from 
Korkmaz et al., 2008, which PDB ID is 1PPF, where yellow represents the catalytic triad and pink represents the 
rest of the structure. 
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4.1.1. Human Neutrophil Elastase inhibition 
 
Under normal physiological conditions, HNE activity is mostly regulated by natural 
endogenous serine protease inhibitors (serpins) (Siedle et al., 2007), such as Ƚ1-proteinase 
inhibitor (Ƚ1-PI), Ƚ2-macroglobulin (Ƚ2-MG), elastase inhibitor (EI), secretory leukocyte 
peptidase inhibitor (SLPI), elafin, and others (Siedle et al., 2007;Winiarski et al., 2012). In 
fact, serpins account for ~2% of the total protein in human plasma, where ~70% is Ƚ1-PI 
(Krowarsch et al., 2003). 
In more detail, serpins are larger proteins, typically composed by 350-500 a.a, and 
capable to adopt different conformations (Krowarsch et al., 2003). These type of inhibitors, 
(serpins) interact in a substrate-like manner, forming exposed binding loops (composed of 
~17 a.a.), preventing the enzyme to act in other subtracts, and consequently inhibiting it 
(Krowarsch et al., 2003;Moreau et al., 2008). 
 
According to literature, natural inhibitors with high MW, like Ƚ1-PI (52 kDa), Ƚ2-MG 
(~190 kDa) and EI (42 kDa), were considered more potent and powerful, but they are less 
effective in contact with other substrates since they are excluded at close contact, whereas 
low MW HNE inhibitors, like SLPI (11.7 kDa) and elafin (6 kDa), can achieve close contacts, 
suggesting advantage of low MW inhibitors (Kawabata et al., 1991;Krowarsch et al., 2003). 
 
As previously mentioned, HNE contributes to ECM degradation in tissue damage, 
being the cause for various inflammatory diseases. Also, as stated in Imokawa, 2008 and 
Takeuchi, 2010 studies, HNE acts in wrinkle formation by repeated UV irradiation and mild 
inflammation (Imokawa, 2008;Takeuchi et al., 2010). Thus, for HNE proteolytic activity 
regulation, various inhibitors have been developed. Whereas inhibitors development 
requires high specificity, low MW, systemic activity and FDA approval (Kawabata et al., 
1991). 
  
In 1991, Kawabata and co-workers have discovered a potent and specific NE inhibitor 
with low MW, N-[2-[4-(2,2-dimethylpropionyloxy)phenylsulfonylamino]benzoyl] 
aminoacetic acid, termed as ONO-5046 (Kawabata et al., 1991), which was further 
developed by Ono Pharmaceutical Co. Ltd (Osaka, Japan) as N-{2-[({4-[2,2-
Dimethylpropanoyl)oxy]phenyl}sulfonylamino]benzoyl} glycine sodium, and named as 
sivelestat (Aikawa et al., 2011). 
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The following figure II.9 represents the chemical structure of this HNE inhibitor, in 
pure state (A) and when associated with sodium, in salt form (B). 
 
  
Figure II.9. Chemical structure of HNE inhibitor, ONO-5046, also named as sivelestat,  in pure state (A) and in 
sodium (Na) salt form (B), wherein the molecular weight is 434.5 and 528.5, respectively. 
 
 
In Kawabata, 1991 studies, ONO-5046 potently inhibit HNE with an half maximal 
inhibitory concentration (IC50) of 0.044 ± 0.003 µM and inhibition constant (Ki) of 0.20 ± 
0.02 µM, using succinyl-Alanine-Alanine-proline-phenylanine-p-nitroanilide (suc-Ala-Ala-
Pro-Phe-pNA) as substrate; and additionally intravenous administration  in guinea pigs 
significantly suppressed NE action in capillary permeability (Kawabata et al., 1991). 
According to Lineweaver-Burk plot analysis of this studies, ONO-5046 inhibition showed to 
be competitive (Kawabata et al., 1991). 
 
Miyazaki, 1998 findings also suggested that ONO-5046 could attenuate acute lung 
injury (ALI) in acute respiratory distress syndrome (Edwards et al.), which is thought to be 
caused by microvascular endothelial cell damaging triggered by HNE (Miyazaki et al., 1998). 
Miyazaki and colleagues showed that ONO-5046 attenuated the neutrophil-dependent 
pulmonary edema in isolated perfused rabbit lungs by inhibiting the alveolar epithelial and 
vascular endothelial injury caused by activated neutrophils and by reduced the shedding of 
thrombomodulin on the endothelium (Miyazaki et al., 1998). In fact, this inhibitor 
(sivelestat) shown to be effective in treatment of patients with ALI associated with systemic 
inflammatory response syndrome (SIRS). As a result was the first drug approved for 
treatment of this disease, being marketed as Elaspol by Ono Pharmaceutical Co. Ltd, and 
approved by FDA in Japan in 2002 (Kitamura et al., 2003;Takada et al., 2003). 
 
Recently, Nawa et al. studies suggested combinatorial use of this inhibitor (sivelestat) 
and trastuzumab as a therapeutically strategy for human epithelial growth factor receptor 
2 (HER2)-positive breast cancer (Nawa et al., 2012). In this therapy, sivelestat prevents the 
effect of HNE in cell growth through HER2 signalling pathway, and in combination with 
trastuzumab, which is a monoclonal antibody against HER2, improves the prognosis of 
patients with HER2-positive breast cancer (Nawa et al., 2012).   
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Regarding HNE inhibition for anti-wrinkling therapy, Imokawa and co-workers 
suggested that application of inhibitors of skin fibroblast elastase would reduce wrinkle 
formation (Imokawa, 2008). They also showed that N-phenetylphosphonyl-L-leucyl-L-
tryptophane (NPLT) and Zingiber officinale (L.) Rose extract act as anti-wrinkling agents by 
inhibiting fibroblast elastase (Imokawa, 2008), where NPLT presented IC50 of 0.050 µM, 
using N-succinyl-tri-alanyl-p-nitroanilide (STANA) as substrate (Tsuji et al., 2001).  
Nonetheless, others elastase inhibitors can be suggested as anti-wrinkle agents, for 
example, hyperoside (IC50 of 0.3 µM), fukinolic acid (IC50 of 0.23 µM) (Siedle et al., 2007), 
oleic acid albumin (IC50 of 0.26-0,42 µM, depending on formulation) (Edwards et al., 2004) 
and other organic oils (Silva et al., 2012), etc.  
 
In conclusion, photoaging process and wrinkle formation can be significantly 
prevented and/or reduced by topical application of elastase inhibitors. For example, 
sivelestat, a potent, selective and FDA approved HNE inhibitor has been shown impressive 
results to control HNE-induced cell damage and consequential associated anomalies and 
diseases, therefore its use as anti-wrinkling agent is promising. 
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Chapter III. Materials and Methods 
 
Materials 
 
Cocoons of Bombyx mori silkworms were kindly supplied by the CRA-APi: Unitá di 
Ricerca di Apicoltura e Bachicoltura (Padova, Italy). In this experimental work we used two 
different batches of B. mori cocoons due to material depletion.  
Taking in consideration that environmental factors (like temperature, humidity, light, 
air and feed) can influence silkworm growth and development, and consequently may affect 
the cocoons’ silk production (Rahmathulla et al., 2004), the final properties of the silk 
fibroin solutions produced from the different batches may differ. However, the CRA-API 
supplier states that the silkworm breed was preserved and the feed was always maintained, 
preventing differences between batches. Even so, to minimize experimental error we 
decided to separate their use as following: the first batch was used in optimization process 
(being prepared as stated in section III.2 and respective results were presented in chapter 
IV) while the second batch was used in further nanoparticles development (being used in 
section III.3 and respective results in chapter V and VI). 
 
The dialysis tubing cellulose membrane of molecular-weight cut off (MWCO) 12-14 
kDa (21 mm of diameter and 33 mm of width) were purchased from Sigma-Aldrich (Spain). 
 
The centrifugal filters devices Amicon Ultra-15 of 3kDa MWCO (volume capacity of 15 
mL, 29.7 mm of diameter and 122 mm of length) used to calculate encapsulation efficiencies 
were purchased from Milipore Corporation (Ireland). 
 
The kinetic assays were performed in microplate format, using 96 wells microplates ȋFͻ͸) from Nunc™ ȋDenmark). 
 
The absorbance of orange IV assay was performed in one milliter Bio-Cell™ quartz 
vessels (108-000-10-40) from 230-700nm and were supplied Izasa, Werfen Group 
(Portugal). 
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Reagents 
 
In general, all the chemicals were purchased from Sigma-Aldrich (Spain), namely, 
lithium bromide (LiBr, purity η ͻͻ%), n-dodecane oil (CH3(CH2)10CH3, purity η ͻͻ %), 
poloxamer 407 (impurity ζ ͳ.Ͳ% water), di(ethylene glycol) ethyl ether (termed as 
transcutol, purity η ͻͻ %), sodium dodecyl sulfate (SDS, purity η ͻͻ %), orange IV (sodium 
4-{(E)-[4-(phenylamino)phenyl]diazenyl}benzenesulfonate; purity η ͻͻ %), elastase from 
human leukocytes (i.e HNE enzyme, purity η ͷͲ U/mg determined by Bradford), synthetic 
substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (i.e. HNE substrate), sivelestat 
sodium salt hydrate (i.e. HNE synthetic inhibitor, purity η ͻͺ % determined by (PLC). 
 
While, the reagent sodium carbonate (Na2CO3) was purchased from Riedel-de-Haën 
(Germany) and Tween 80 was purchased by Merck-Schuchardt. 
 
To be noted, all chemicals and materials used along this work were stored and manipulated according to the manufacturer’s instructions and safety practices. )n addition, 
all chemicals were used as supplied without any further purification. 
 
 
Equipment 
 Various equipment’s were used along this experimental work. To facilitate, a list of the used equipment’s with their specific use in this work and supplier is summarized in a 
table (Table Annex. 2) in Annex III. 
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Methods 
1. Preparation of Regenerated Silk Fibroin (RSF) Solution  
 
Silk fibroin stock solutions were prepared as previously described (Sah et al., 
2010;Wray et al., 2011). Initially, the cocoons were cut and cleaned from debris. Then, raw 
silk of the Cocoons Bombyx mori silkworms were boiled 3 times in an aqueous solution of 
Na2CO3 (0.05 %) during 30 minutes and washed several times with deionized water for 
sericin removal. 
The dried degummed silk was then dissolved in 9 M LiBr for 3 hours at 60 °C and after 
filtration, the resulting SF solution was dialyzed in cellulose tubing (MWCO of 12-14 kDa) 
against double-deionized water for at least 3 days at room temperature to remove the 
neutral salts and LiBr. 
Final solution of regenerated silk fibroin (RSF) was quantified by Bradford method 
for further nanoparticle formation studies, and stored at 4ºC for a maximal period of 2 
weeks. Bradford method was performed according to protocol from Sigma-Aldrich 
technical bulletin of the Bradford Reagent. This procedure involves Bio-Rad protein assay 
(Bio-Rad Laboratories, GmbH) based on the shift of absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue G-2SO at  595 nm when binding to protein occurred, 
and using RSF as a standard protein. Absorbance measurements were performed by 
Ultraviolet-Visible (UV-Vis) spectrophotometry using SynergyM with Genͷ ™ Microplate 
Data Collector and Analysis Software (Bio-Tek Instruments, Inc., Vermont, USA). The 
calibration curve of RSF used for Bradford quantification is presented in Figure Annex.1, in 
Annex IV. 
 
 
2. Process optimization of Silk Fibroin Nanoemulsions 
 
In order to optimize the nanoparticles formation, SF nanoemulsions were produced 
by an oil-in-water (o/w) emulsification using two high-energy methods, ultrasonication and 
high pressure homogenization (HPH). RSF solutions were emulsified in different 
concentrations and oil-in-water (o/w) emulsion ratios, using n-dodecane as oil organic 
phase and RSF protein dissolved in the water phase.  
According to this initial optimization, a silk fibroin nanoparticles production guideline 
was established for further studies, since results enable method, parameters and conditions 
selection. 
 
 
  
CHAPTER III. MATERIALS AND METHODS 
 
 
38 
2.1. Optimization by Ultrasonic Emulsification method 
 
Nanoemulsions by ultrasonic emulsification, to further obtain nanoparticles, were 
prepared by an adaptation of Bang and Suslick method (Bang et al., 2010), according to 
previous studies conducted by our research group (Silva et al., 2012;Silva et al., 2012;Silva 
et al., 2012). 
The ultrasonic emulsification method was carried in a thermo-stated bath at 4ºC, for 
3 minutes with percentage amplitude of 40 % as power delivery. Samples (16 mL) were 
placed for reaction in an open glass cell (diameter 19 mm and height 75 mm). The 
equipment was composed of a probe type ultrasound source (20 kHz Sonics and Materials Vibrocell ™ CV 33) fitted with a 3 mm diameter titanium micro-tip. For temperature control, 
the sonochemical reactor was controlled via a thermo-stated water bath with a freezer 
exchanger placed within a thermo jacket cell. Temperature was monitored throughout 
using K type thermocouples. Pictures of this equipment are presented in Figure III.1. 
The volume of RSF (silk fibroin solution, water phase) at specific concentration was 
first added to the ultrasonic flask, and the n-dodecane (oil phase) was added for last. Then, 
the bottom of the high intensity ultrasonic horn was positioned at the interface of this two 
phases and the sonochemical treatment was initiated. 
After emulsification, the flasks were kept at 4ºC for at least 24h until phase separation 
was established. Then, the n-dodecane oil phase (at the top of the flask) was gently removed 
with a micropipette. The removed n-dodecane oil was measured, verifying that almost the 
volume of oil used was recovered (up to 91 % of oil recover). Samples were closed with a 
rubber cap and stored at 4ºC for further characterization.  
The ultrasonic emulsification was tested for 3, 5 and 10 g/L of RSF concentration and 
for 10/90, 20/80 and 40/60 of o/w emulsion ratios. 
 
  
Figure III.1. Pictures of the Ultrasonic equipment used along this work for silk fibroin nanoparticles production. 
The samples placed in ultrasonic flasks were putted in contact with an ultrasound probe. 
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2.2. Optimization by High Pressure Homogenization (HPH) method 
 
Production of nanoparticles by high pressure homogenization was based in previous 
works of our research group (Gonçalves et al., 2013;Nogueira et al., 2013). 
SF-NPs production by high pressure homogenization (HPH) method was evaluated in 
two different operating systems, a single-stage and a double-stage system. The following equipment’s are presented in Figure ))).ʹ. 
The single-stage HPH equipment (Figure III.2-A), an Emulsiflex™-C3 (supplied from 
Avestin, Inc., Canada), where homogenization of 20 mL of sample was carried at 2000 bar 
for 12, 18, 24, 30 and 36 homogenization cycles. By this single-stage method, the following 
conditions were tested: 3, 5 and 10 g/L of RSF concentration and for 10/90, 20/80 and 
40/60 of o/w emulsion ratios. 
The double-stage HPH equipment (Figure III.2-B), an APV-2000™ (supplied from SPX 
Flow Technology, APV Manufacturing, Poland) and 100 mL samples passed through two 
homogenizing devices connected in series, the first stage at 580-600 bar and second stage 
at 240-250 bar, for 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 homogenization cycles. 
Samples by HPH emulsification using double-stage equipment were tested for 5 and 10 g/L 
of RSF concentration and for 10/90, 20/80 and 40/60 of o/w emulsion ratios. 
In both systems, the n-dodecane oil phase was removed from the HPH emulsified 
samples according to the same procedure applied for ultrasonic method (section 2.1 of 
chapter III). Again, the samples were closed and stored at 4°C for further studies. 
 
 
Figure III.2. Pictures of the High-pressure homogenization ȋ(P() equipment’s used along this work for silk 
fibroin nanoparticles production, single-stage HPH Emulsiflex™-C3 (A) and double-stage HPH APV-2000™ (B). 
  
A       B 
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3. Preparation of Silk Fibroin Nanoemulsions and Nanoparticles 
 
SF nanoemulsions for further studies (after optimization) were produced by double-
stage HPH using an APV-2000™ homogenizer. Briefly, 80 mL of 10 g/L of RSF solution were 
emulsified with 20 mL of n-dodecane (20/80 ratio of o/w) by double-stage HPH for 22 
homogenization cycles, at 580-600 bar and 240-250 bar of first and second stage of 
pressure, respectively. Being these conditions considered as standard/optimized. 
The reproducibility of this method was assessed by repeating the SF-NPs production 
process at the same optimized conditions. Then, they were statistically analyzed (n=3) 
according to mean and standard deviation. 
 
All compounds to add or incorporate into the silk fibroin formulations were dissolved 
in the water phase, as performed in previous works of our research group (Nogueira et al., 
2013;Silva et al., 2012;Silva et al., 2012). 
 
 
3.1. Stabilizers incorporation in silk fibroin nanoemulsions formulation 
 
Stability studies of silk fibroin nanoparticles was performed by combining several 
stabilizers with RSF solution and then, emulsified at the optimized production conditions. 
The tested stabilizers were poly(ethylene glycol)-block-poly(propylene glycol)-block-
poly(ethylene glycol) (often termed as poloxamer 407), di(ethylene glycol) ethyl ether 
(commonly called by transcutol), polyoxyethylene 80 sorbitan monooleate (usually 
referred as tween 80) and sodium dodecyl sulfate (SDS). The respective molecular weight, 
molecular formula and structure of the tested stabilizers are summarized in Annex V. 
Briefly, each of these stabilizers was completely dissolved in 1% of concentration in 
the RSF solutions (80 mL) and then, emulsified with 20 mL of n-dodecane at the optimized 
conditions (22 homogenization cycles and 580-600 bar and 240-250 bar of first and second 
stage of pressure, respectively). 
 
3.2. Loading Compounds in Silk Fibroin Nanoemulsions 
 
Incorporation of a model-drug, orange IV, and HNE inhibitor, sivelestat, in silk fibroin 
nanoparticles was also tested. Their chemical information is presented in Annex VI. 
Orange IV at 50 M, 75 M and 100 M and sivelestat at 100 M were individually 
added to 80 mL of RSF solution (10g/L of concentration). After complete dissolution, these 
solutions were placed in the double-stage homogenizer, layered with 20 mL of n-dodecane 
(20/80 of o/w ratio), and emulsified at the standard conditions.  
In addition, their stability effect in the SF-NPs was also assessed. 
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4. Human Neutrophil Elastase (HNE) studies 
 
This dissertation intends to produce a human neutrophil elastase (HNE) enzyme 
inhibition system, in order to apply it as an anti-wrinkling agent. Therefore is important to 
first conduct a control of this enzyme normal behaviour, i.e. evaluate the HNE kinetic 
without inhibition, and then with an inhibitor, in this case, sivelestat. 
 
4.1. HNE activity determination and Inhibition by Sivelestat 
 
The human neutrophil elastase (HNE) activity was assayed with the chromogenic 
synthetic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (MeOSuc-Ala-Ala-
Pro-Val-pNA), in accordance with the protocol supplied by Sigma-Aldrich. In this assay, the 
enzymatic hydrolysis of the substrate is followed by p-nitroaniline release, allowing it 
detection by the increase of absorbance. 
The normal HNE activity assay consisted in mixing 15 µL of HNE enzyme at 0.5 U/mL 
with MeOSuc-Ala-Ala-Pro-Val-pNA substrate at various concentration (25, 50, 100, 200, 
400, 600, 800 and 1000 µM), then the final volume was completed with the reaction buffer 
0.1M HEPES + 0.5M NaCl, pH 7.5. The assay control (blank) consisted only in buffer and 
substrate mixture, without HNE.  
The HNE Inhibition assays with synthetic inhibitor sivelestat consisted in incubating 
15 µL of HNE (0.5 U/mL) and 15 µL of sivelestat at various concentration (0.1, 0.25, 0.5, 1, 
1.5, 2, 2.5 and 5 µM) for 5 minutes. Then, the mixture was added to the microplates, which 
already contain the reaction buffer and various concentration of MeOSuc-AAPV-pNA 
substrate (25, 50, 100, 200, 400, 600, 800 and 1000 µM). 
All enzyme assays were conducted at 37°C for 10 minutes in microplates of 300 µL 
and absorbance were measured in triplicate (n=3) at 405 nm by UV-Vis spectrophotometry.  
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5. Characterization of developed Silk Fibroin Nanoparticles 
 
The SF nanoemulsions were further characterized in order to determinate the 
produced NPs properties. 
In optimization process, initial characterization consisted in mean diameter and 
heterogeneity of the produced nanoparticles using dynamic light scattering (DLS) in 
ZetaSizer Nano ZS equipment. Then, in a second phase, the nanoparticles yield through 
formation efficiency was determined by Bradford method using UV-Vis spectrophotometry. 
SF-NPs further developed with the optimized parameters were characterized as 
referred above but also, according to surface charge using laser Doppler anemometry (LDA) 
in ZetaSizer Nano ZS equipment. 
For NPs incorporated with orange IV and sivelestat, encapsulation efficiency was 
determined for both, drug release studies of incorporated orange IV were performed by 
dialysis bag method and HNE inhibition studies for incorporation with sivelestat was 
performed by kinetic HNE studies. 
Then, secondary structure conformation changes were evaluated by Fourier 
Transform Infrared (FTIR) Spectroscopy, before and after emulsification, being also studied 
the differences between non-encapsulated and encapsulated nanoparticles. 
 
 
5.1. Yield of Silk Fibroin Nanoparticles 
 
In nanoemulsification process, not all SF protein used in formulation forms 
nanoparticles. Therefore is important to determinate the yield (%) of nanoparticle 
production, which can be determined by Formation efficiency, presented in the following 
equation (Equation III.1). 
 ܨ݋ݎ݉�ݐ�݋݊ ܧ݂݂���݁݊�� ሺ%ሻ = [Protein]initial − [Protein]final[Protein]final × ͳͲͲ 
 
Equation III.1. Determination of efficiency of nanoparticles formation, also referred as yield of nanoparticles. 
 
Formation efficiency of SF-NPs was performed by ultracentrifugation using Allegra® 
X-15R Centrifuge with an FX6100 rotor (Beckman Coulter, Inc., California, EUA), at 10,000 
rpm (10,976 g) for 60 minutes, in order to separate the free SF protein of the nanoparticles. 
The supernatant of each sample was collected and quantified by Bradford method in 
UV-Vis spectrophotometry. RSF protein was used as calibration, calibration curve 
presented in Annex IV. The determination was conducted in triplicate (n=3). 
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5.2. Size and PDI by Dynamic Light Scattering (DLS) 
 
The produced SF-NPs were first characterized according to size by mean diameter 
values and size distribution by polydispersity index (PDI) values. These measurements 
were conducted immediately after the emulsification process and over time (up to 2-5 
weeks) in order to study their stability, being the samples stored at 4ºC.  
These characterization was determined by dynamic light scattering (DLS), also 
known as photonic correlation spectroscopy (PCS), being this technique further detailed in 
Annex VII. 
These measurement were evaluated in ZetaSizer Nano ZS, a Malvern Zetasizer 
equipment (Worcestershire, United Kingdom), where 800 µL of sample were placed in 
disposable low volume polystyrene cells (ZEN0112) and analyzed at 25°C using a He-Ne 
laser of 633 nm and a detector angle of 173°. In addition, the Malvern dispersion technology 
software version 7.01 (DTS) (Worcestershire, UK) was used with multiple narrow mode 
(high-resolution) data processing, and mean size (nanometer), and error values were 
considered, being analyzed in triplicate (n = 3). 
 
 
5.3. Surface charge by Laser Doppler Anemometry (LDA) 
 
Nanoparticles were further characterized according to their surface charge, for that 
the zeta-potential ȋɃ) value of the samples was determined by laser Doppler anemometry 
(LDA) using ZetaSizer Nano ZS (same equipment used for size and PDI determination, 
section III.5.2). The LDA method is further detailed in Annex VIII. 
The zeta-potential measurements were evaluated in the same conditions as in size 
and PDI determinations (section III.5.2), with the difference that samples were placed in 
folded capillary cells (DTS1060). 
 
 
5.4. Stability studies 
 
To evaluate the stabilizers, orange IV and sivelestat effect in silk fibroin nanoparticles, 
measurements of mean diameter and polydispersity index were performed at time of 
production and over time, once a week, from 2-4 weeks. Evaluation of these results 
consisted in statistical determination of standard deviation. 
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5.5. Encapsulation efficiency of Orange IV in Silk Fibroin Nanoparticles 
 
Orange IV was used through this experimental work as a model-drug compound in 
order to predict and define a drug release profile.  
This compound was loaded in the silk fibroin nanoparticles during high-pressure 
homogenization (HPH) process, as described in loading Compounds in silk fibroin 
nanoemulsions (section III.3.2). 
After emulsification process, samples were placed in centricon tubes (MWCO of3 kDa) 
and ultracentrifuged at 5,000 x g (6,749 rpm) for 45 minutes. According to this method, the 
free (non-encapsulated) orange dye passed through the tube filter since its molecular 
weight is lower than 3 kDa, whereas when orange IV is loaded in the nanoparticles, their 
molecular weight is higher, limiting their passing thought the filter.  
Then, the orange IV concentration of the supernatant (liquid that passed thought the 
filter) was measured in triplicate (n=3) at 240 nm by UV-Vis spectrophotometry. This 
quantification was performed using a standard calibration curve of orange IV, presented in 
Figure Annex.1, in Annex IX. 
Finally, the encapsulation efficiency of orange IV-loaded SF nanoparticles was 
determined in triplicate, according to Equation III.2. 
 ܧ݊��݌ݏݑ݈�ݐ�݋݊ ܧ݂݂���݁݊�� ሺ%ሻ = [orange IV]initial − [orange IV]final[orange IV]final × ͳͲͲ 
 
Equation III.2. Determination of encapsulation efficiency of orange IV-loaded in nanoparticles. 
 
 
 
5.6. In vitro Orange IV Release Studies by Dialysis bag method 
 
Before loading the drug sivelestat in the SF-NPs, studies with a model-drug compound 
orange IV were first conducted to establish a model of incorporation and drug release. For 
that, in vitro release behaviour of SF-NPs loaded with 100 µM of orange IV were assessed in 
dialysis bag method, according to the procedure used in various studies (D'Souza et al., 
2006;Nounou et al., 2006;Shazly et al., 2008;Silva et al., 2012). Briefly, samples (total 
volume of 2 mL) were placed in dialysis bag (cellulose membrane, MWCO 12-14 kDa), sealed 
and immersed in 10 mL of deionized water, with continuous magnetic stirring (200 rpm) at 
room temperature for 140 hours. 
Release studies were performed in triplicate (n=3) for the following conditions: SF-
NPs incorporating orange IV, free orange IV (87 µM) dissolved in 10g/L of RSF solution and 
solution of orange IV (87 µM), with and without HNE enzyme (0.5 U/mL).  
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To be noted, the used sample of SF-NPs incorporated with orange IV was retrieved 
from the top of the tube after ultracentrifugation applied in encapsulation efficiency of 
orange IV in SF-NPs determination (section III.5.5), so this sample only possessed the 
incorporated orange IV. 
Then, at predetermined time intervals, dialysis volume were withdrawn and replaced 
again with deionized water. Orange IV concentration was measured in triplicate at 240 nm 
by UV-Vis spectrophotometry, using a standard calibration curve of orange IV, presented in 
Annex IX. 
To better understand the orange IV release behavior, the orange IV release kinetics 
was evaluated by fitting the release data in a mathematical empirical relationship defined 
by the Ritger-Peppas equation (Ritger et al., 1987), presented above in Equation III.3. 
 
 M�M∞ = ݇ × ݐ�  
 
Equation III.3. Ritger-Peppas equation used to define release behaviour of compounds from polymeric systems, 
where Mt,/M∞, k, t and n represent the fractional release of the compound, constant incorporating characteristics 
of the macromolecular network system, release time and diffusional exponent characteristic of the release 
mechanism, respectively. Based in Ritger et al., 1987 publication. 
 
 
The diffusional exponent, n value, indicates the mechanism of transport of the 
released compound to the exterior medium, in this case the orange IV release (Ritger et al., 
1987). Considering Silva et al. method, this value can be determined by transforming the 
Ritger-Peppas equation in a linear function, where n is the slope value of the plot log (% 
released) versus log (t), as described in Equation III.4 (Silva et al., 2012). 
 
 ݈݋݃ ( M�M∞) = ݈݋݃ሺ% releasedሻ = ݈݋݃ ሺݐሻ × ݊ + log ሺ݇ ሻ 
 
Equation III.4. Ritger-Peppas modified equation used to determinate n value, where Mt,/M∞, % released, k, t 
and n represent the fractional release of the compound, the percentage of compound released, constant 
incorporating characteristics of the macromolecular network system, release time and diffusional exponent 
characteristic of the release mechanism, respectively. Based in Ritger et al., 1987 and Silva et al., 2012 
publications. 
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5.7. Encapsulation efficiency of Sivelestat in Silk Fibroin Nanoparticles 
 
Sivelestat was also loaded in the silk fibroin nanoparticles during emulsification by 
high-pressure homogenization (HPH), as stated in section III.3.2. This method is similar to 
the one applied for orange IV (section III.5.5) differing in the quantification assay since 
sivelestat could not be individually detected by UV-Vis Spectrometry. 
Emulsified sample of sivelestat 100 µM loaded in silk fibroin nanoparticles were 
placed in centricon tubes (MWCO of 3 kDa) and ultracentrifuged for 45 minutes at 5,000 x 
g (6,749 rpm). The encapsulated sivelestat was confined in the top of the tube while the free 
(non-encapsulated) sivelestat passed through the tube filter (supernatant).  
Sivelestat concentration in the supernatant was further submitted to kinetic assays at 
405 nm in microplates of 300 µL by UV-Vis spectrophotometry. In this kinetic assay, the 
enzyme used was human neutrophil elastase (HNE) at 0.5 U/mL and N-methoxysuccinyl-
Ala-Ala-Pro-Val-p-nitroanilide (MeOSuc-Ala-Ala-Pro-Val-pNA) as substrate. Quantification 
was performed in triplicate (n=3) using a standard calibration assay of the HNE inhibition 
studies (section III.4.1) by extrapolation. 
 
5.8. HNE inhibition studies of silk fibroin Nanoparticles 
 
The HNE inhibition effect of the developed SF-NPs loaded with sivelestat was 
assessed as described in section III.4.1. 
Briefly, 15 µL of HNE (0.5 U/mL) was incubated with 15 µL of SF-NPs loaded with 100 
µM of sivelestat sample for 5 minutes. Then, the incubation mixture was added to the 
microplates, previously set with the reaction buffer 0.1M HEPES + 0.5M NaCl, pH 7.5 volume 
and MeOSuc-Ala-Ala-Pro-Val-pNA substrate at different concentrations (25, 50, 100, 200, 
400, 600, 800 and 1000 µM). The kinetic assays at 37°C for 10 minutes and absorbance were 
measured in triplicate at 405 nm by UV-Vis spectrophotometry. 
The control (blank) of the assay, i.e.  without inhibitor sivelestat, consisted in the 
following: a control without enzyme HNE using only buffer and substrate mixture; a control 
to establish the normal kinetic behaviour of the HNE enzyme using buffer, substrate and 
HNE enzyme mixture; and a control to evaluate the SF effect in HNE activity using buffer, 
substrate, HNE and RSF solution. 
In this assay, we used the silk fibroin and sivelestat nanoemulsion sample retrieved 
from the top of the tube after ultracentrifugation applied in encapsulation efficiency of 
sivelestat in SF-NPs determination (section III.5.6). This way, the sample used does not 
possess residual (non-encapsulated) sivelestat, i.e. only possess the incorporated sivelestat. 
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5.9. Structural analysis by Fourier Transform Infrared (FTIR) 
Spectroscopy 
 
Silk fibroin nanoparticles were analyzed by Fourier transform infrared (FTIR) 
spectroscopy to quantitatively assess their protein secondary structure, namely the 
differences that emulsification process may cause (Yampolskaya et al., 2005). This method 
was applied for the following samples: silk fibroin solution at 10g/L of concentration, SF 
nanoparticles, SF nanoparticles loaded with 100 µM of orange IV and SF nanoparticles 
loaded with 100 µM of sivelestat. 
The FTIR spectra of the lyophilized silk fibroin solution and produced nanoparticles 
were recorder in transmission mode between wavenumber 600 and 4000 cm–1 using Jasco 
FT/IR 4100 spectrometer equipped with attenuated total reflectance (ATR) accessory 
(JASCO, Inc., Easton, USA), with 128 scans and a resolution of 8 cm–1. The resulting spectra 
were further carbon dioxide (CO2) removed according to Jasco software, and in addition to 
the fact that samples were lyophilized, it allows a more accurate analysis. 
Gaussian deconvolution of Amide I band region (wavenumber between 1600 and 
1700 cm–1) was analyzed using OriginPro 8.5 software (OriginLab Corporation, MA, USA). 
In deconvolution analyze, a linear baseline was fitted; the number of components and their 
peak position were determined according to the second derivative spectrum of this same 
region; and the secondary structure content was calculated from the areas of the assigned 
peak as percentage fraction of the total area of the Amide I range. Using Gaussian function, 
all data were treated manually in three fitting modes: first, the base line was held fixed  and 
fitted while intensity and bandwidth was allowed to vary, then, the base line and bandwidth 
were fixed and fitted again, and finally, the base line and center peaks were fixed and fitted 
once more. The deconvulated frequencies were then assigned to the respective secondary structure ȋȾ-sheet, Ⱦ-turns, random-coil, Ƚ-helix and 310-helix) according to Kong et al., 2007 
and Dong et al., 1992 publications (Dong et al., 1992;Dong et al., 1992;Kong et al., 2007). 
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Chapter IV: Optimization Production Process of SF-NPs 
by High-energy Emulsification Methods 
 
 
 
In order to develop SF-NPs for HNE inhibitor incorporation it is important to optimize 
the nanoparticles production process. Since the emulsification process are extensively 
applied in biopolymeric nanoparticles for cosmetic nanoparticles, we decided to use this 
method (Buzea et al., 2007;Patel et al., 2011;Pathak et al., 2009;Sundar et al., 2010). Briefly, 
emulsification method involves mixture of an oil and water phases into emulsions, that can 
consequently lead to emulsions at a nano range and to nanoparticle formation when 
extreme high shear stress is applied (Mason et al., 2006;Mason et al., 2006). Therefore, we 
used two high-energy methods, ultrasonication and high pressure homogenization (HPH). 
Besides, since the NPs production method delineates the final SF-NPs characteristics, we 
tested various conditions of production, namely SF concentration and emulsion ratio. 
In this work, the selection of the oil phase and the optimization variables were based 
on the previous works of our research group (Gonçalves et al., 2013;Nogueira et al., 
2013;Silva et al., 2012;Silva et al., 2012). In detail, choice of oil n-dodecane was based in 
Silva and co-workers studies, in which they produced Bovine Serum Albumin (BSA), Human 
Serum Albumin (HSA) and Silk Fibroin (SF) nanoparticles with this oil and obtained great 
NPs yield, diameter and PDI by sonochemical treatment and also showed that release of this 
oil from the nanoparticles reduced the activity of human neutrophil elastase (HNE) (Silva et 
al., 2012). 
This optimization will enable us to design the best possible method and respective 
conditions to produce silk fibroin nanoparticles with the desirable characteristics at the less 
possible resources. 
 
In this optimization step, the produced nanoparticles were first characterized by 
simple measurement of mean diameter and polydispersity index (PDI), in which we 
intended to obtain the smallest possible values, namely ideal nanoparticle diameter would 
be less than 200 nm and ideal PDI would be below 0.1. To be noted, PDI value features the 
NPs size distribution and ranges from 0 to 1, being 1 indicative of large variation of size and 
0 of absent variation (Schiffelers et al., 2005). 
Then, the best considered formulations were further characterized by formation 
efficiency determination, in which the purpose was to obtain the highest possible 
nanoparticles yield values.  
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The results for nanoparticles production by ultrasonic emulsification and by high-
pressure homogenization are presented in distinct sections below. This separation will 
enable a better selection of the optimized conditions. 
 
 
1. SF-NPs production by Ultrasonic Emulsification  
  
The ultrasonication method is extensively used for nanoemulsions generation and 
further nanoparticles production (Anton et al., 2008;Bang et al., 2010;Lovelyn et al., 
2011;Naik et al., 2012). In this process, the high-energy involved is created by the 
ultrasound waves, produced by the sonifier probe device (Bang et al., 2010). These 
ultrasound waves generate mechanical depressions and compressions, which lead to 
formation of cavitation bubbles that tend to implode (Anton et al., 2008;Bang et al., 
2010;Naik et al., 2012).  When the bubbles implode, the accumulated energy is released 
leading to entropy and instability (Bang et al., 2010).  Since the cavitational implosion is 
localized and the horn was positioned in the interface of n-dodecane and silk fibroin 
solution, the oil/water interface becomes unstable, causing oil droplet eruption into the 
water phase (Anton et al., 2008;Bang et al., 2010;Naik et al., 2012). The intensification of the 
shock events will consequently lead to disruption of the droplets into nano range, resulting 
in nanoparticles production (Anton et al., 2008;Bang et al., 2010;Naik et al., 2012). 
The efficiency of the nanoparticles produced by ultrasonic emulsification depends on 
the emulsion composition, namely the composition of the both oil and water phases and 
their oil-in-water ratio, and the method parameters, such power input (amplitude) and 
duration time (Anton et al., 2008;Naik et al., 2012). 
 
In this experimental work, silk fibroin nanoparticles were produced with n-dodecane 
as oil phase and regenerated silk fibroin (RSF) solution as water phase, at various oil/water 
ratio (10/90, 20/80 and 40/60) and using various concentrations of  RSF (3, 5 and 10 g/L), 
being then characterized according to mean diameter and polydispersity index  (PDI) . The 
results of ultrasonic optimization are presented in Figure IV.1, being the mean diameter and 
PDI represented in columns and points, respectively. 
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Figure IV.1. Effect of ultrasonic emulsification on silk fibroin nanoparticles production at different RSF 
concentrations and n-dodecane/RSF solution ratios. Being mean diameter in nanometers (nm) and 
polydispersity index value (PDI) presented in columns and points, respectively. 
 
 
 
According to Figure IV.1, it is possible to observe some tendency that increase of SF 
concentration leads to smaller nanoparticles for oil/water ratio of 10/90 and 20/80, but 
not for 40/60. In emulsions, proteins form a macromolecular layer surrounding the 
dispersed particles, consequently stabilizing the nanoemulsions and the formed 
nanoparticles (Floury et al., 2000). Therefore, an increase of concentration of protein SF 
promotes cover of the formed particles more easily, allowing a better control of the 
nanoparticles structure, namely their size, since it prevents them from losing their form 
(Silva et al., 2012;Silva et al., 2012). In addition, silk fibroin used in nanoemulsions also 
decreases the surface tension between the oil/water interface, facilitating the 
emulsification process (Floury et al., 2000), hence increasing of SF concentration lead to 
increases the nanoemulsion formation. 
Regarding the oil content, we verified that almost all samples present larger 
nanoparticles when the n-dodecane quantity is increased. This agrees with other studies 
that report an increase in mean diameter when the oil content in oil-in-water emulsions was 
increased (Floury et al., 2000). According to Pandolfe et al., 1995 studies, the increase of oil 
content decreases the interaction of the agents present in the aqueous solution (Floury et 
al., 2000;Pandolfe, 1995). Therefore, the increase of n-dodecane limits the silk fibroin 
protein stabilizing benefits referred above, which increases the droplets size, leading to 
larger mean diameter particles (Floury et al., 2000).  
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Giving this facts, higher SF concentration and lower content of organic phase enables 
production of smaller nanoparticles with a consistent distribution, i.e. smaller mean size 
diameter and PDI values. 
In conclusion, by ultrasonic emulsification method we obtained the smaller 
nanoparticles (~430 nm) using 10 g/L of RSF and 10/90 of o/w ratio, wherein the 
respective polydispersity index (PDI) value was 0.251. Regarding this production method, 
we considered this formulation as the best, even so the obtained characteristics were not 
ideal, being necessary to evaluate the effect of high-pressure homogenization process in 
nanoparticles production.  
 
 
2. SF-NPs production by High-pressure homogenization (HPH) 
 
Emulsification by high-pressure homogenization was conducted by two types of 
homogenization, a single and a double-stage system. A single-stage homogenization system 
contains only one homogenization device, being one stage of pressure involved, whereas a 
double-stage system possesses two homogenization devices connected in series.  
 
 
2.1. Production using HPH single-stage system 
 
Nanoemulsions of n-dodecane and RSF were tested at the following conditions: 
oil/water ratio of 10/90, 20/80 and 40/60 and at RSF concentrations of 3, 5 and 10 g/L. 
The nanoparticles were characterized according to mean diameter and polydispersity index 
(PDI), being this measurements mainly performed in 6 cycles, from 6 to 36 cycles of 
homogenization. The results for silk fibroin nanoparticles production by HPH single-stage 
are above, in Figure IV.2, in which (A), (B) and (C) present the values obtained for RSF at 3, 
5 and 10 g/L, respectively. 
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Figure IV.2. (A) Effect of emulsification by single-stage HPH (EmulsiFlex™-C3) on silk fibroin nanoparticles 
production for 3 g/L of RSF concentration at various n-dodecane/RSF solution ratios, along several 
homogenization cycles. Being mean diameter in nanometers (nm) and polydispersity index value (PDI) 
presented in columns and lines, respectively. 
 
 
 
 
Figure IV.2. (B) Effect of emulsification by single-stage HPH (EmulsiFlex™-C3) on silk fibroin nanoparticles 
production for 5 g/L of RSF concentration at various n-dodecane/RSF solution ratios, along several 
homogenization cycles. Being mean diameter in nanometers (nm) and polydispersity index value (PDI) 
presented in columns and lines, respectively. 
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Figure IV.2. (C) Effect of emulsification by single-stage HPH (EmulsiFlex™-C3) on silk fibroin nanoparticles 
production for 10 g/L of RSF concentration at various n-dodecane/RSF solution ratio s, along several 
homogenization cycles. Being mean diameter in nanometers (nm) and polydispersity index value (PDI) 
presented in columns and lines, respectively. 
 
 
In general, Figure IV.2 shows that almost all obtained nanoparticles possess a mean 
diameter lower than 200 nm, which was better than the previous studies performed with 
ultrasonic emulsification. As already mentioned, nanoparticles are formed due to 
involvement of the disruptive forces, and since more disruptive forces are involved in high-
pressure homogenization than in ultrasound (Lovelyn et al., 2011), it is expected that 
homogenization process can give better results. 
The forces involved in HPH are hydraulic shear, intense turbulence, shear stress, 
cavitation, impingement and increase of temperature, in which turbulence is thought to be 
the dominant mechanism (Floury et al., 2000;Lovelyn et al., 2011). Briefly, in turbulence the 
dispersed phase break-up leads to small droplets and the fluid motion results in droplets 
collision, leading to coalescence (droplets are combined into one) but also to breakage 
(Floury et al., 2000). The equilibrium between this two effects consequently increases 
nanoparticle formation (Floury et al., 2000). In addition, this method involves large 
variations of pressure and fluid velocity, causing significant energy release, allowing droplet 
size reduction of the produced emulsions and it may also improve their stability over time 
(Floury et al., 2000).  
Finally, the high temperature involved in HPH method also influences the size of the 
droplets by affecting the viscosity of the oil and aqueous phase (Floury et al., 2000). Along 
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the homogenization process, the energy involved is partially dissipated as heat, increasing 
the fluid temperature, which then causes decreases the fluid viscosity and reduces the 
interfacial tension between oil/aqueous phases, facilitating the droplets formation at small 
range (Floury et al., 2000). Even so, it is important to highlight above a critical temperature 
that proteins can be significantly affected, they can unfold and aggregate (Floury et al., 
2000). For example, the protein secondary structure can lose their repeated motifs, leading 
to conformational changes of stable structures to the unstable random-coil configuration, 
which will be further discussed in chapter VI.  
 
According to other studies, it is expected the decrease of the mean diameter of the 
nanoparticles along the homogenization process, i.e. with the increase of the 
homogenization cycles since this prolongation leads to more intensive disruptive forces, 
causing droplets disruption into even smaller droplets (Anton et al., 2008;Bang et al., 
2010;Floury et al., 2000;Naik et al., 2012). In our experimental work, this behaviour was not 
observed, in fact correlation between size and number of cycles is controversial since it 
suggests that increase in number of cycles produces larger nanoparticles. This may suggest 
the method instability, wherein the formed nanoemulsions are very unstable and silk 
fibroin protein cannot stabilize the formed nanoparticles (Silva et al., 2012;Silva et al., 
2012). 
We also observed that increase of homogenization cycles causes PDI values to 
decrease, suggesting that the developed emulsions become more homogenous along the 
prolongation of the HPH emulsification, narrowing the NPs size distribution. However, as 
Figure IV.2 (C) shows, this tendency does not occur when using 10 g/L of RSF, which 
disagrees with previous reports that state higher concentration of protein stabilized the 
nanoparticles, leading  to a more uniform size distribution (Floury et al., 2000;Silva et al., 
2012;Silva et al., 2012). 
 
Taking into account that this method is unstable, we suggest it to be unable to control 
the formulation and the nanoparticles formation, probably because more energy is 
required. This behaviour is well-described by Floury and co-workers, in which they showed 
that at low rates of HPH, cluster and aggregates of droplets are formed (Floury et al., 2000). 
In this case, the hydrodynamic forces involved are insufficient, and incapable to disrupt this 
flocs structures, this causes viscosity to increase and consequently of leads to larger size 
droplets at a dispersed range (Floury et al., 2000). 
Therefore, we suggest that an increase of the hydrodynamic forces involved in the 
emulsification process may enable the flocs disruption, leading to production of smaller 
nanoparticles (Floury et al., 2000). Taking this into account, we decided to increase the 
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pressure involved in HPH emulsification, namely by applying two stages of pressure in the 
homogenization process. 
Even so, in HPH single-stage optimization, we considered the formulation using 10 
g/L to be the best since the formed nanoparticles possess a mean diameter variation 
between 75 and 125 nm, while others vary from 100 to 225 nm. 
 
 
2.2. Production using HPH double-stage system 
 
Since the previous methods, ultrasonic and single-stage HPH emulsification, were not 
able to produce optimal silk fibroin nanoparticles, we decided to test a double-stage HPH, 
because according to the manufacture company APV, most emulsions when applied in a 
double-stage system show improvement in droplet size reduction, allowing the production 
of smaller nanoparticles.  
For that, we tested 5 and 10 g/L of RSF solution at 10/90, 20/80 and 40/60 of 
organic/aqueous phase, using as oil phase n-dodecane and aqueous phase the SF solution. 
The homogenization process was conducted for 28 cycles, wherein nanoparticles 
characterization was performed every 2 in 2 cycles. 
The obtained measurements of mean diameter and PDI values using 5 and 10 g/L of 
silk fibroin solution are presented in Figure IV.3 (A) and (B), respectively. 
In this experimental work, we did not test 3 g/L of RSF concentration because HPH 
singles-stage results showed that this condition was less stable than the others since it 
presented a more significant size variation, but mainly due to the knowledge that protein 
higher concentration leads to smaller nanoparticles (Floury et al., 2000;Silva et al., 
2012;Silva et al., 2012). 
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Figure IV.3. (A) Effect of emulsification by double-stage HPH (APV-2000™) on silk fibroin nanoparticles 
production for 5 g/L of RSF concentration at various n-dodecane/RSF solution ratio s, along several 
homogenization cycles. Being mean diameter in nanometers (nm) and polydispersity index value (PDI) 
presented in columns and lines, respectively. 
 
Figure IV.3. (B) Effect of emulsification by double-stage HPH (APV-2000™) on silk fibroin nanoparticles 
production for 10 g/L of RSF concentration at various n-dodecane/RSF solution ratio s, along several 
homogenization cycles. Being mean diameter in nanometers (nm) and polydispersity index value (PDI) 
presented in columns and lines, respectively. 
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During the homogenization process, the pre-emulsion characteristics are improved 
along the increase of number of homogenization cycles, and consequently the nanoparticles 
that forms (Anton et al., 2008;Bang et al., 2010;Floury et al., 2000;Naik et al., 2012). This 
nanoparticles improvement is mainly observed by the decrease of the droplets mean 
diameter and reduction of their distribution size (Anton et al., 2008;Bang et al., 2010;Floury 
et al., 2000;Naik et al., 2012). 
 
Studies have suggest that the mean diameter evaluation along the homogenization 
process consists in two main trends (Floury et al., 2000). 
In the first trend, the mean diameter and size distribution of the nanoparticles 
decreases with the increase of the number of cycles (Floury et al., 2000). This behaviour is 
a result of the intensification of the pressure that allows an increase of the energy input, 
leading to disruptive forces intensification which disrupt and decrease the larger droplets 
into smaller sizes (Floury et al., 2000). Even so, as we already mentioned, this behaviour is 
only achieved when the energy and pressure involved are large enough to cause the 
disruptive forces (Floury et al., 2000). 
 
However, when the homogenization pressure and energy involved is too high it shows 
a saturation-like behaviour (Barnadas-Rodríguez et al., 2001;Floury et al., 2000). Indeed, at 
a given pressure, the increase of number cycles over a critical value does not result in mean 
diameter and size distribution decrease (Barnadas-Rodríguez et al., 2001). 
In this second phase, the involved high pressure negatively affects the emulsion 
formation and the produced nanoparticles. According to Brandl et al. studies with 
liposomes, this behaviour is due to the instability of the formed droplets which rapidly fuse 
with one another, leading to larger droplets, known as coalescence effect (Barnadas-
Rodríguez et al., 2001;Brandl et al., 1990). The authors also suggest that the decrease of the 
droplets beyond the cycle’s critical value would require a larger pressure and energy input 
(Barnadas-Rodríguez et al., 2001;Brandl et al., 1990). Pandolfe and others studies also 
emphasises this idea (Barnadas-Rodríguez et al., 2001;Floury et al., 2000;Pandolfe, 1995). 
In addition, studies have shown that severe processing involved in this method can 
lead to deterioration of the involved protein (Floury et al., 2000), therefore we suggest that 
increase of the involved forces, namely the increase of the cycles, could lead to instability of 
the silk fibroin protein and further destabilization, preventing their action in facilitating and 
stabilizing the nanoparticles formation into smaller sizes. 
The cycle critical value depends on the emulsion composition, namely the oil and 
water phase composition (Barnadas-Rodríguez et al., 2001). In fact, the protein used in the 
emulsion extensively affects this behaviour since the protein facilitates and stabilizes the 
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nanoparticles formation, and therefore the protein characteristics (such as molecular 
weight, conformational structure, properties and others) influence the emulsification 
process (Floury et al., 2000). 
 
This mentioned behaviours were observed in our experiment. For some cases, we 
only observed the first trend (decrease of the diameter and size distribution with the 
increase of number of cycles), namely in Figure IV.3 (A) for 10/90 and in Figure IV.3 (B) for 
20/80 and 40/60. In this cases, we did not observed the second trend because the increase 
of cycles need to be further evaluated, i.e. more cycles had to be tested. 
For Figure IV.3 (A) 20/80 and 40/60 and Figure IV.3 (B) 10/90, the second trend was 
observed since the diameter and size distribution over a specific cycle started to increase. 
For this conditions, we observed that the critical cycle value was 16 and 20. 
 
As we mentioned above, higher silk fibroin concentrations enable a better 
emulsification process (Floury et al., 2000), hence we evaluated the formation efficiency for 
10g/L of RSF at 10/90, 20/80 and 40/60 of n-dodecane/SF solution ratio. The nanoparticles 
yield values are presented in the following table. 
 
 
Table IV.1. Silk Fibroin Nanoparticles yield production (formation efficiency) for 10 g/L of RSF concentration 
at various n-dodecane/RSF solution ratio for 28 cycles of homogenization, using double-stage HPH (APV-
2000™) emulsification. 
Sample 
SF-NPs Yield 
Formation Efficiency (%) 
SF-NPs 10/90 of n-dodecane/RSF 74.802 ± 2.462 
SF-NPs 20/80 of n-dodecane/RSF 79.134 ± 0.715 
SF-NPs 40/60 of n-dodecane/RSF 76.159 ± 0.814 
 
According to Table IV.1, the formulation 10g/L at 20/80 of n-dodecane/SF solution 
ratio obtained higher nanoparticles yield, which is due to the fact that high oil contents allow 
production of more stable nanoparticles (Floury et al., 2000) and  in this condition we did 
not observe a saturation-like behaviour, therefore the formed nanoparticles were more 
stable at 20/80 than 10/90 of  n-dodecane/SF solution ratio. Additionally, we observed that 
10/90 formulation possess a high deviation standard, emphasizing it instability due to this 
saturation effect (Barnadas-Rodríguez et al., 2001;Brandl et al., 1990;Floury et al., 
2000;Pandolfe, 1995). 
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Comparing this results with the Figure IV.3 (B), we conclude that the best formulation 
was obtained for 10g/L at 20/80 of n-dodecane/SF solution ratio, at 22 cycles, in which we 
obtained silk fibroin nanoparticles with 183 nm of mean diameter and polydispersity index 
(PDI) of 0.089. We considered this cycle as the lower possible cycle that allowed to achieve 
lower values of mean diameter and polydispersity index (PDI), besides it also enables 
prevention of the saturation-like since for further cycles the size is maintained constant.  
 
In conclusion, we will use these optimization results, namely the optimized conditions 
(double-stage HPH, formulation 10g/L at 20/80 of n-dodecane/SF solution ratio, at 22 
cycles) to further develop nanoparticles for elastase inhibitor incorporation.  
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Chapter V: Incorporation in SF-NPs for Transdermal Delivery 
 
After optimization and selection of the best parameters for silk fibroin nanoparticles, 
we proceeded to the main purpose of this dissertation work, incorporation of the HNE 
inhibitor sivelestat into the developed silk fibroin nanoparticles to act as an anti-wrinkling 
agent. However, we also performed stabilization studies in order to evaluate their potential 
application as a cosmetic. 
This chapter comprehends three main incorporations into the developed SF-NPs at 
the established optimized conditions: incorporation of various stabilizers to evaluate their 
potential in stabilizing the cosmetic formulation; incorporation of a model-drug, orange IV, 
to establish a model of incorporation and drug release profile; and finally, incorporation of 
the HNE inhibitor, sivelestat,. In order to better elucidate, results of this chapter were 
divided in three main sections, being these present ahead. 
 
 
However, before presenting and discussing the results for these sections, we will 
clarify some issues, namely differences between Bombyx mori SF material and the double-
stage high-pressure homogenization method reproducibility. 
As referred in materials and reagents section of chapter III, due to material depletion, 
we had to use two different batches of Bombyx mori cocoons in optimization process and in 
the following of the experimental work. Since we used a different batch for optimization 
process and another for the further studies, the optimization results obtained with the first 
batch, which were presented in chapter IV, may vary from the ones obtained with the 
second batch. Hence, in Table V.1, we present the size diameter, PDI, zeta-potential and 
formation efficiency values for the optimized conditions, and also the initial values 
according to optimization of chapter IV, for comparison. 
 
Table V.1. Characteristics of the silk fibroin nanoparticles produced during the initial optimization process 
(presented in chapter IV) and after optimization with the optimized conditions, by double-stage high-pressure 
homogenization for 10 g/L of RSF at 20/80 o/w ratio, being the homogenization cycle presented in parentheses. 
Characterization 
SF-NPs produced during 
the initial optimization 
SF-NPs produced with the 
optimized conditions 
Mean Diameter (nm) 
183.1 
(22 cycles) 
140.7 ± 1.852 
(22 cycles) 
Polydispersity index (PDI) 
0.089 
(22 cycles) 
0.249 ± 0.004 
(22 cycles) 
Zeta-Potential (mV) 
-21.2 ± 1.674 
(28 cycles) 
-33.3 ± 0.473 
(22 cycles) 
SF-NPs Yield 
Formation Efficiency (%) 
79.134 ± 0.715 
(28 cycles) 
60.097 ± 3.033 
(22 cycles) 
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According to Table V.1, we observe some differences between the results obtained by 
the two batches of cocoons of B. mori silkworms. However, in further analysis we observed 
that these differences were constant for all conditions, in fact the tendency observed in 
optimization results maintained. In other words, the parameters selected as optimal 
remained the same, differing only in the obtained values. In conclusion, although these 
differences are significant, we do not consider them relevant since the only purpose of 
optimization process was to help design and select the best parameters for silk fibroin 
nanoparticles production, and these ǲoptimal parametersǳ did not change. 
Furthermore, we suggest that the differences of mean diameter and PDI values may 
be due to the usage mode of the homogenization equipment. During the optimization 
process of HPH, the equipment was stopped for sample measurements and again started, at 
every 2 in 2 cycles. While, after optimization, the equipment was only stopped at the 22nd 
cycle, since this was the optimized parameter. According to this, we suggest that the 
stop/start action could influence the emulsification process. For example, we suggest that 
these interruptions may lead to energy loss, which could affect the involved disruptive 
forces, or on the contrary, could increase the energy involved since it could lead to a 
malfunction on controlling the pressure. Indeed, as mentioned above extensive variables 
are involved along the HPH process, so process interruption could affect these variables and 
consequently affect the nanoparticles characteristics. Even so, Middelberg studies highlight 
the importance that the homogenizer process is maintained without interruption 
(Middelberg, 2000).  
In addition, differences of zeta-potential and formation efficiency cannot be 
comparable since they were evaluated for different cycles. 
 
Finally, we also assessed the double-stage high pressure homogenization 
reproducibility by comparison of mean diameter and PDI values. For that, we repeated the 
silk fibroin nanoparticles production process at the optimized condition (10 g/L of silk 
fibroin at 20/80 of n-dodecane/RSF solution ratio at 22 cycles of homogenization) by 
double-stage HPH APV-ʹͲͲͲ™ and then determinate the statistical parameter of standard 
deviation. The results showed a low standard deviation of NPs mean diameter and PDI 
values, 9.683 nm and 0.015, respectively, therefore we concluded that this SF-NPs 
production method was reproducible. 
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1. Stabilizers effect in Silk Fibroin Nanoparticles 
 
 
This experimental work consisted, first, in incorporation of various stabilizers into 
the optimized SF-NPs formulation, namely poly(ethylene glycol)-block-poly(propylene 
glycol)-block-poly(ethylene glycol) (often named by poloxamer 407), polyoxyethylene 80 
sorbitan monooleate (usually referred as tween 80), di(ethylene glycol) ethyl ether 
(commonly termed as transcutol) and sodium dodecyl sulphate (SDS). 
 
As referred above, surfactants are amphiphilic surface-active molecules, which  
highly solubilize in one of the phases and stabilize the formed conformation, namely the 
nanoparticles (Mason et al., 2006;Mason et al., 2006). 
Polymeric surfactants are one of the most effective stabilizers, since they control and 
prevent flocculation and coalescence effects (Tadros, 2011). In fact, these types of 
stabilizers are extensively used in cosmetic and personal care preparations, nanoemulsions 
(Tadros, 2011). 
 
In detail, poloxamer 407, also known as pluronic F127, is a non-ionic polymeric 
surfactant of the A-B-A block graft type, where A is poly(ethylene glycol), the ǲstabilizingǳ 
chain and B is poly(propylene glycol), the ǲanchorǳ chain (Dumortier et al., 2006;Tadros, 
2011). The hydrophilic lipophilic balance (HLB) of poloxamer 407 is 22 at 22°C, being 
considered as a solubilizer of hydrophobic compounds (Dumortier et al., 2006). 
 
Other non-ionic surfactant is tween 80 derived from polyethoxylated sorbitan and 
oleic acid (Kim, S et al., 2013;Kloet et al., 2002). This compound is also called by polysorbate 
80 and is a detergent and a solubilizing agent, presenting HLB value of 15 (Kloet et al., 2002). 
 
Transcutol is a powerful stabilizer agent since it possesses great optimal solubilizing 
properties, and is consider as a skin penetration enhancer since it increases significantly 
percutaneous penetration (Mura et al., 2000). This short-chain alcohol is mainly used as 
additive due to their weakly amphiphilic character. Transcutol, like many other alcohols 
molecules are considered as a co-surfactant, being frequently used in combination with 
surfactants or others stabilizing molecules. Several authors suggest that this co-surfactant 
molecules are capable of concentrating and aggregating the surfactant molecules in the 
particles interphase layer, improving the surfactant self-assembly around the particles, and 
their stabilizer effect. To be noted, transcutol possesses a HLB value of 4, being considered 
as lipid soluble (Mandal, S et al., 2011;Solanki et al., 2012). 
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SDS, also known as sodium lauryl sulphate (SLS), is a small-molecule anionic 
surfactant capable of adsorbing the oil droplets surfaces within homogenizers (Qiang et al., 
2011). Similar to poloxamer 407, SDS acts as a gelling agent since it causes SF molecules to 
self-assembly into stable Ⱦ-sheets structures, and to associate in nanoparticles by stronger 
hydrophobic and electrostatic interactions  (Wu, X et al., 2012). In addition, SDS presents 
and HLB value of 40, and also possesses an amphipathic structure, being also considered as 
a detergent, like tween 80 (Lo, 2003). 
 
 
As mentioned, the stabilizers were incorporated in the formulation by dissolution in 
the RSF solution (water phase) before the emulsification process at the optimized 
conditions (10 g/L of RSF at 20/80 o/w ratio, for 22 cycles of homogenization). These 
stabilizers were added only in 1% of concentration because their use should be limited to a 
minimum possible level, to prevent any toxic and hypersensitivity reactions (Stevanovic et 
al., 2009). 
Then, their effect was evaluated by measuring the mean diameter and PDI values over 
time, once a week, for 2-4 weeks. As control, we used silk fibroin nanoparticles without any 
stabilizer. These results are presented in the following Figure V.1, where the mean diameter 
is presented in columns and PDI values in lines. 
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Figure V.1. Stability evaluation of silk fibroin nanoparticles incorporated with various stabilizers, namely 
tween 80, transcutol, SDS and poloxamer 407, on mean diameter in nanometres (nm) and polydispersity 
index value (PDI) along several weeks. 
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According to Figure V.1, the size and size distribution of SF-NPs without any stabilizer 
(control) was considered stable only for 2 weeks, since the mean diameter and PDI 
increases significantly at the 2nd week (~200 nm) and it kept increasing. This shows the 
need to incorporate a stabilizer in the formulation. 
 
Regarding the studied stabilizers, we considered that the most efficient stabilizer was 
transcutol because the mean diameter and PDI values variation over the weeks was smaller 
than the others stabilizers. In fact, for transcutol we obtained smaller standard deviation 
value for mean diameter values. According to other studies, this effect may be due to 
transcutol co-surfactant action. In which, we suggested that transcutol improves SF protein 
stabilization activity in the nanoparticles by helping adsorption of SF molecules around the 
nanoparticles (Mandal, S et al., 2011;Solanki et al., 2012). Besides, transcutol possesses a 
great potential use in cosmetic application, especially, for this work, in the development of 
an anti-wrinkling agent, since it can be used as a drug permeation enhancer due to their 
solubilizing properties and ability in drug cutaneous retention (Mura et al., 2000). 
Even so, stabilizers tween 80 and SDS also showed great stability for PDI values, in 
which, SDS presented the lower standard deviation for PDI values. SDS ability in stabilizing 
nanoparticles size and size distribution over time may be due to the fact that it is a gelling 
agent, since it causes SF protein to be orientated around the nanoparticles in a more stable 
and strong conformation (Wu, X et al., 2012), preventing the coalescence and flocculation 
effect. 
Tween 80 showed mean diameter values higher than the others but after the 1st week, 
size and size distribution stabilized, and the standard deviation between this period was 
smaller than for others stabilizers. The tween 80 effect in particles size agrees with 
Asasutjarit et al., 2013 studies, in which they suggest that tween 80 acts as amphiphilic 
molecules, being deposited in the particles, and preventing them from interact with others, 
thus, controlling the size and size distribution (Asasutjarit et al., 2013). In fact, some reports 
state that detergents, like tween 80 and SDS, are capable of enhancing proteins 
conformational stability, preventing them from unfolding and protecting from aggregation 
(Arakama et al., 2000). So, silk fibroin protein, and consequently silk fibroin nanoparticles 
are stabilized by these detergent molecules due to their amphiphilic structure. 
However, it is important to highlight that their ability to modify proteins structure 
due to their amphiphilic nature, can also cause downsize effects, namely protein 
denaturation (Caligur, 2008). In fact, tween ͺͲ is considered as a ǲmildǳ detergent because 
it is less likely to denature proteins while SDS is considered a ǲharshǳ detergent (Caligur, 
2008). Even so, in this case, SF is not likely to denature since the compounds were added to 
the formulations at a very low concentration, 1% (Caligur, 2008).  
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Poloxamer 407 was not able to stabilize the SF-NPs since it presented higher values 
of mean diameter higher than the control condition, being the mean diameter and PDI 
increased over time. In fact, this condition did not present any nanoparticles formation since 
the mean diameter was higher than 1 µm and the sample was too disperse (PDI value of 1). 
This behaviour can be explained by the fact that the propylene oxide chain are not strong 
enough to ideally absorb in the particle, therefore they cannot influence the particle stability 
like the others stabilizers (Tadros, 2011). We, then, predict that increase of poloxamer 407 
concentration would increase their effect and improve the particles stability (Tadros, 2011). 
 
 
To better understand these results, we evaluated the surface charge of the formed 
nanoparticles by zeta-potential determination. In detail, zeta-potential is the electrical 
potential of the surface of hydrodynamic shear, which is around the colloidal particles 
(Bunjes, 2005). According to this, is possible to measure indirectly the surface potential of 
these nanoparticles by the zeta-potential values (Bunjes, 2005). 
The particle surface charge is mainly responsible for the stability of this particle in a 
dispersion or solution, in fact, this charge depends on the concentration and type of ions 
involved in the surround medium of this particle (Malvern, 2005). Taking all this into 
account, it is possible to evaluate the stability of a particle in a specific environment by zeta 
potential determination (Greenwood et al., 1999;Hanaor et al., 2012;Malvern, 2005). 
In various studies, it is shown that high absolute values of zeta-potential indicate 
more stable dispersion since high charge (positive and negative) increase the electrostatic 
repulsion of other molecules, and consequently inhibit agglomeration and flocculation 
(Greenwood et al., 1999;Hanaor et al., 2012). 
In general, stabilizers are deposited in the surface of the particles and change the 
electrical potential around the interface of the particle and medium, hence, incorporation of 
stabilizers in these formulation will affect the zeta potential values (Stevanovic et al., 2009). 
Considering this, zeta potential measurements were performed after production of the silk 
fibroin nanoparticles for the tested stabilizers, being this presented in Figure V.2. As control 
conditions, we used regenerated silk fibroin solution without stabilizer before being 
emulsified and after. 
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Figure V.2. Surface charge evaluation of silk fibroin nanoparticles incorporated with various stabilizers, namely 
tween 80, transcutol, SDS and poloxamer 407, by zeta-potential determination in millivolts (mV) at time of 
production. 
 
 
The results of the Figure V.2 highlight the previous discussion. In which, mean 
diameter and PDI stabilization over time is related to the zeta-potential values, namely the 
high values of zeta-potential indicate stable emulsion, as established by other studies 
(Greenwood et al., 1999;Hanaor et al., 2012). 
According to Figure V.2, incorporation with transcutol and SDS showed better 
stability results since results for these conditions presented larger magnitude of the zeta-
potential values. 
In addition, as predicted, poloxamer 407 showed lower zeta-potential values, which 
allow us to conclude that this stabilizer was the less effective in SF-NPs stabilization. 
Finally, comparison of zeta-potential values of RSF solution and SF-NPs showed that 
the nanoparticles formation increases stability, which goes according to the literature (Silva 
et al., 2012;Silva et al., 2012;Zhao et al., 2013). Since it is thought that HPH process may lead 
to conformational changes from unstable random-coil to stable Ⱦ-sheets (Silva et al., 
2012;Silva et al., 2012), we considered that this result might be due to this effect, which will 
be further discussed in the next chapter (chapter VI). 
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Finally, we measured the nanoparticle yield for the stabilizers tween 80, transcutol 
and SDS, since poloxamer 407 was considered as a non-efficient stabilizer. As control, we 
used SF-NPs without any stabilizer. The obtained formation efficiency values are presented 
in Table V.2. 
 
 
Table V.2. Silk Fibroin Nanoparticles yield production for various stabilizers by determination of formation 
efficiency. 
Sample 
SF-NPs Yield 
Formation Efficiency (%) 
SF-NPs (control) 60.097 ± 3.033 
SF-NPs with 1% Tween 80 26.450 ± 4.822 
SF-NPs with 1% Transcutol 60.943 ± 3.277 
SF-NPs with 1% SDS 76.259 ± 2.001 
 
 
Higher formation efficiency was obtained for SDS, however according to the previous 
results their stability effect was not optimal, whereas transcutol showed a better stability 
over time and their formation efficiency value was considered acceptable. 
In conclusion, we considered transcutol as the most efficient stabilizer since it 
presented good mean diameter and PDI stability, large magnitude of zeta-potential value 
and acceptable nanoparticles yield (~61%). In addition, transcutol possesses the advantage 
of being a drug permeation enhancer (Mura et al., 2000). 
 
Even so, since the formation efficiency value of transcutol was not ideal and for SDS 
we obtained a better yield, we suggest a combination of these two stabilizers. We predict 
that combination of the co-surfactant transcutol and surfactant SDS, would increase the SF-
NPs stability since transcutol would increase SDS effect (Mandal, S et al., 2011;Solanki et al., 
2012) and improve the SF-NPs further permeation in the skin (Mura et al., 2000). 
 
 
  
CHAPTER V: INCORPORATION IN SF-NPs FOR TRANSDERMAL DELIVERY 
 
 
74 
2. Incorporation of a model-drug, orange IV, in SF-NPs 
 
In this second step, incorporation of a model-drug compound, orange IV, was 
conducted to establish a model of incorporation and drug release profile. The obtained 
results will allow selection of the best concentration of drug to incorporate and to predict 
the drug release from the nanoparticles at different conditions, namely in absence and 
presence of HNE enzyme. 
 
Briefly, orange IV (4-{(E)-[4-(phenylamino)phenyl]diazenyl}benzenesulfonate) is an 
orange dye, also named as tropaeolin 00, benzenesulfonic acid or acid orange 5, with 
C18H14N3NaO3S as molecular formula (Uddin et al., 2010;Wang, HY et al., 2006). Due to the 
azo group, this compound is extensively used in textile industry as a dye, being also used to 
in silk dyeing (Uddin et al., 2010). 
Several studies have reported dyes as models for incorporation in various devices, 
mainly because dyes enable simple evaluation of the incorporation process, in a 
quantitative way but also by visual detection (DeLauder et al., 2000;Shu et al., 
2000;Teichmann et al., 2007;Wu, BM et al., 1996). Considering this, we decided to use the 
dye orange IV as a model-drug, since it quantification is simply detected by UV-Vis at 240 
nm and is possible to visually detect it exit from the nanoparticles. 
In addition, orange IV possesses sulphonic groups (S=O) and aromatic rings (Uddin et 
al., 2010) and a smaller structure like sivelestat, in fact their molecular weight is very similar 
to sivelestat. To be noted, in the dye selection, we had to take into account their availability 
in our research lab. 
 
First characterization of the SF-NPs incorporated with model-drug orange IV 
consisted in evaluation of this compound effect in the developed nanoparticles, namely in 
their size and size distribution and this parameters stability over time. For that, the 
developed nanoparticles loaded with orange IV at various concentrations were evaluated 
by measuring mean diameter, PDI and zeta-potential. In addition, determination of the 
formation and encapsulation efficiency for the considered best concentrations of orange IV 
was also performed. 
The results of size and size distribution stability along time are presented in Figure 
V.3 and zeta-potential measurement at time of production are presented in Figure V.4. 
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Figure V.3. Stability evaluation of silk fibroin nanoparticles incorporated with various concentrations of the 
model-drug orange IV (50, 75, 100 and 1000 µM), on mean diameter in nanometres (nm) and polydispersity 
index value (PDI) along several weeks. 
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Figure V.3 suggests improvement of the size and size distribution of the developed 
nanoparticles stability when incorporating the model-drug orange IV, since the mean 
diameter and PDI values of the SF-NPs incorporated with orange IV show some persistence 
over time while the values for SF-NPs without incorporation tended to increase over time. 
This results may suggest that orange IV possesses the ability to stabilize the 
nanoparticles, probably due to establishment of  hydrophobic interactions and van der 
Waals forces with the SF structure by the azo (N=N) and sulphonic groups (S=O) (Uddin et 
al., 2010). In addition, this stabilization effect might also be related to the orange IV ability 
to increase gelation in silk fibroin, since gelation increases the emulsion stability 
(Matsumoto et al., 2006). Since orange IV is an acid dye, dissolution of orange IV decreases 
the pH and causes SF protonation, which decreases the repulsions and leads to the 
mentioned interactions, enabling the SF-NPs with orange IV stabilization and  size and size 
distribution control (Matsumoto et al., 2006). 
This behaviour was proved visually. After dissolution of orange IV in silk fibroin, we 
observed that the consistency of the solution increased slightly, in which this increase 
showed to be related to the increase of orange IV concentration. Also, when carrying the 
HPH emulsification with incorporation of 1 mM of orange IV, the sample showed some 
increase in their viscosity and along cycles it turned into a gel. 
In order to better understand this stabilization process, SF secondary structure will 
be further evaluated by FTIR, in chapter VI. 
 
Regarding the size and size distribution results, we considered that incorporation of 
100 µM of orange IV enable to obtain smaller SF-NPs and allowed better stabilization of the 
mean diameter and PDI values since the standard deviation of size and size distribution was 
smaller (~25 nm and 0.06, respectively). Even so, incorporation of 50 and 75 µM of orange 
IV also showed stability along time, since the standard deviation values for size and size 
distribution was also smaller, being only higher than for 100 µM due to the slightly increase 
of mean diameter and PDI values at week 4. 
In addition, incorporation of 1 mM of orange IV showed larger SF-NPs and a higher 
size distribution than the others concentrations of orange IV, however it showed good 
stabilization of the size and size distribution over time. 
According to this, determination of zeta-potential at time of production and along the 
weeks were conducted to help us select the best concentration of orange IV to incorporate, 
being these present in the following Figure V.4. 
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Figure V.4. Surface charge evaluation of silk fibroin nanoparticles incorporated with various concentrations of 
the model-drug orange IV (50, 75, 100 and 1000 µM) by zeta-potential determination in millivolts (mV) at time 
of production. 
 
As mentioned above, incorporation with 1 mM of orange IV showed increase in the SF 
gelation, being this proven by their higher zeta-potential value (-62.5 mV) in Figure V.4. 
Since the gelation process occurred during the HPH emulsification, we considered this 
condition as non-optimal because it could lead to HPH equipment malfunction. 
Considering the rest of incorporation with orange IV samples, we observed that 50, 
75 and 100 µM showed high zeta-potential values and excellent stability of the surface 
charge over time. 
 
Finally, the formation and encapsulation efficiency were determined to help us 
selecting the ideal concentration to incorporate. Since we eliminated incorporation of 1mM 
of orange IV, we only determined these parameters for incorporation with 50, 75 and 100 
µM of orange IV, being these results presented in the following table, Table V.3. 
 
Table V.3. Silk Fibroin Nanoparticles yield production (formation efficiency) and encapsulation efficiency for 
incorporation of various concentrations of the model-drug orange IV (50, 75, 100 and 1000 µM). 
Sample 
SF-NPs Yield 
Formation Efficiency (%) 
SF-NPs  
Encapsulation Efficiency (%) 
SF-NPs (control) 60.097 ± 3.033 - 
SF-NPs loaded with 50 µM Orange IV 74.930 ± 3.522 26.518 ± 0.705 
SF-NPs loaded with 75 µM Orange IV 72.289 ± 2.065 83.096 ± 1.355 
SF-NPs loaded with 100 µM Orange IV 66.879 ± 2.147 91.446 ± 0.082 
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As it is possible to observe in Table V.3, higher formation and encapsulation efficiency 
was obtained for incorporation of 50 and 100 µM of orange IV, respectively. In general, all 
conditions showed an increase of the formation efficiency when incorporating orange IV. 
This results, as already discussed, may be due to the stabilization effect of orange IV in SF 
protein, which further stabilizes the nanoparticles production. 
Considering the previous results and Table V.3, we considered that the best 
concentration to incorporate in SF-NPs is 100 µM, since allow us to obtain smaller 
nanoparticles (140 nm) at an acceptable size distribution (PDI of 0.3), with a high absolute 
zeta-potential value and presented good formation and encapsulation efficiency (~67 and 
91 %). 
Hence, we selected this condition as optimal concentration to incorporate in SF-NPs 
and in the following studies we will use this value. 
 
 
2.1. In vitro Orange IV Release Studies 
 
In a second characterization, the model-drug orange IV release from the SF-NPs with 
100 µM of orange IV was evaluate over time, in absence and presence of human neutrophil 
elastase (HNE) enzyme (0.5 U/mL). This results will enable us to predict the sivelestat 
release profile from the nanoparticles in control conditions (absence of HNE enzyme) and 
when applied to the skin as anti-wrinkling agent (presence of HNE enzyme). 
The release of drug from proteinaceous nanoparticles was studied by dialysis bag 
diffusion technique since it is considered as the most popular method to study the drug 
release (D'Souza et al., 2006;Nounou et al., 2006;Shazly et al., 2008;Silva et al., 2012). 
The result from the orange IV release studies is presented in the following Figure V.5, 
where dashed and filled lines represent absence and presence of HNE enzyme, respectively. 
In order to better elucidate the orange IV release at initial time, we emphasis this initial 
behaviour in a smaller graph. 
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Figure V.5. In vitro model-drug cumulative Orange IV Release studies by dialysis bag method for silk fibroin 
nanoparticles incorporated with 100 µM of orange IV in absence and presence of human neutrophil (HNE) 
enzyme at 0.5 U/mL. As controls were used free orange IV dissolved in water and dissolved in RSF solution. 
 
In Figure V.5, we can observe that when orange IV was incorporated in SF-NPs, their 
release was controlled at some extent. In fact, it showed a slower release than to the controls 
conditions. SF-NPs released nearly 40% of the entrapped orange IV at 20 hours while free 
orange IV (without being encapsulated) dissolved in water and in silk fibroin solution came 
out nearly 80% and 60% at this time, respectively. 
This free orange IV exit to the outside solution differed according to the dissolved 
medium. More specifically, free orange IV dissolved in water showed a higher dispersion to 
the exterior than when dissolved in RSF solution. We suggest that this difference may be 
due to the possible interactions that orange IV may establishes with SF protein by their azo 
(N=N) and sulphonic groups (S=O) (Uddin et al., 2010), as already discussed. In fact, these 
results also agree with the previous suggestions, in which orange IV might increase gelation 
in SF (Matsumoto et al., 2006). Considering this, we hypothesized that SF association to 
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orange IV and further gelation, prevents the orange IV exit, slowing their exit rate; whereas 
in water, orange IV exits to the outside medium at a faster rate. 
 
 
In general, the main challenges in developing proteinaceous particles is their 
incomplete release and initial burst release (Yeo et al., 2004). Various authors suggested 
that the incomplete release is related to the protein instability since conformational and 
biological integrity of proteins are extensively affected by the involved particles production 
methods (Yeo et al., 2004). In this case, as mentioned above, the severe disruptive forces 
involved in HPH emulsification process for SF-NPs production may lead to silk fibroin 
protein damage (Floury et al., 2000). 
 
According to Figure V.5, majority of the samples showed an incomplete orange IV 
release, in fact even for control conditions, we observed that free orange IV was not 
completely detected. In more detail, incorporated orange IV release from SF-NPs only 
achieved 50% of total release, while free orange IV dispersion when dissolved in water and 
in silk fibroin solution showed an ~90% and ~75%. This incomplete orange IV exit might 
be due to SF instability that could lead to SF protein aggregation and/or nonspecific 
adsorption within the nanoparticles (Yeo et al., 2004;Crotts et al., 1997;Crotts et al., 
1997;Kim, HK et al., 1999), however it may also be related to the HNE enzyme action. 
 
Since the aim of this study is for topically apply these SF-NPs in the skin as prevention 
of wrinkle formations by inhibiting the HNE enzyme, the release studies were carried out in 
absence and presence (at 0.5 U/mL) of this enzyme, in order to mimic the in vivo conditions. 
Comparing the behaviour of samples in absence and presence of HNE enzyme, we observed 
significant differences total exit of orange IV.  
In general, orange IV total release is lower for samples with HNE enzyme. Considering 
the catalytic activity of HNE enzyme (Owen et al., 1999), we suggest that this enzyme might 
cleave the orange IV dye compound, affecting their structure, for example their aromatic 
rings. Considering this, the orange IV absorbance might altered, preventing their detection 
by UV-Vis and lead to colourless of the orange IV. 
In fact, the control of orange IV in solution suggests our hypothesis, since orange IV 
was completely detected in absence of HNE, while in presence of this enzyme, nearly 10% 
of orange IV was not detected. Moreover, orange IV when dissolved in RSF solution showed 
the same incomplete behaviour, in which we also suggest that 10% of orange IV was not 
detected due to the HNE action. To be noted, visual evaluation of the sample that showed an 
incomplete release were colourless, emphasizing this hypothesis.  
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Regarding the orange IV release from the SF-NPs, we suggested that the incomplete 
release is caused by the SF instability as described by other studies (Yeo et al., 2004;Crotts 
et al., 1997;Crotts et al., 1997;Kim, HK et al., 1999). In this case, results showed that HNE did 
not affect the orange IV release from the SF-NPs, which might be due to the fact that SF-NPs 
protect their content, in this case orange IV, against HNE activity. 
To evaluate this hypothesis further studies had to be conducted, for example by 
assessing and measuring the human neutrophil elastase activity in various conditions, 
namely in RSF solution and when dissolved in orange IV solution. This could be achieved by 
a non-specific protease activity assay adapted for human neutrophil elastase. 
 
 
Initial burst is defined as high release of a compound in the first hours of the release 
method, in which DDS possessing higher initial burst are considered as ineffective (Yeo et 
al., 2004). Therefore, in order to assess the drug release profile of the DDS and their in vivo 
efficacy and safety is important to evaluate the onset and duration of burst (D'Souza et al., 
2006). 
As observed in Figure V.5, the release profile of orange IV from SF-NPs showed a very 
low initial burst, in which only 5% of orange IV was released in the first hour and then was 
followed by a controlled release along time (plateau). Additionally, the control of orange IV 
dissolved in RSF solution presented a high initial burst, but we do not consider it relevant 
because it does not involve release per se, since orange IV is not encapsulated. 
 
According to the literature, the initial burst can be associated to two events: first it 
can be caused by the diffusion of the non-entrapped drug molecules, dispersed around the 
particles surface (Muthu et al., 2009;Yeo et al., 2004); or due to the poor ability of 
encapsulation and stabilization of the compound inside of the particle (Yeo et al., 2004). 
Considering the first case, orange IV initial burst release may be due to the free orange 
IV dispersed in the nanosuspension and/or adsorbed on the SF-NPs (Muthu et al., 2009). In 
this situation, the initial release can be reduced by improving the separation of the free drug 
(non-encapsulated) from the drug incorporated in the particles (Muthu et al., 2009;Silva et 
al., 2012;Yeo et al., 2004). 
According to the second possibility, the SF-NPs are not able to prevent the orange IV 
release which may be due to the particles instability and/or their morphology, in which the 
orange IV might be escaping through pores and cracks (Yeo et al., 2004). Even so, this event 
is less likely since the observed initial release was minor, hence the initial release is mainly 
due to the dispersion of orange IV molecules near the SF-NPs (Silva et al., 2012). 
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Even so, to better understand the mechanism involved in drug release from polymeric 
devices, it is important to analyse them by mathematical models (Ritger et al., 1987;Ritger 
et al., 1987;Siepmanm et al., 2001;Silva et al., 2012), being all based in Fickian diffusion 
equation, presented in Equation III.3 (Ritger et al., 1987;Ritger et al., 1987;Siepmanm et al., 
2001;Silva et al., 2012). Considering this, evaluation of mechanism transport of the released 
orange IV to the exterior medium was assessed by determination of the n value (diffusional 
exponent). The n value was determined for orange IV release from SF-NPs, in absence and 
presence of HNE enzyme, being this presented in Table V.4. Additionally, in order to 
evaluate if the results are reliable, the correlation coefficient (r2) of the linear equation of 
plot log (Mt/M∞) versus log (t) used to determine n values was also determined.  
 
 
Table V.4. Orange IV release kinetic data obtained from fitting into modified Ritger-Peppas equation (Equation 
III.4) from silk Fibroin nanoparticles incorporated with model-drug orange IV, in absence and presence of HNE 
enzyme (0.5 U/mL). 
SF-NPs loaded with 100 µM Orange IV  n R2 
Without HNE enzyme 0.556 0.977 
With 0.5 U/mL of HNE enzyme 0.593 0.980 
 
 
 
The most important rate-controlling mechanism of DDS are diffusion, swelling and 
erosion (Siepmanm et al., 2001), which can be defined by the n value. According to Ritger et 
al. and Siepmann et al. studies and considering our sample particles spherical, the 
diffusional exponent, n, can possess the following values: 0.43 indicates a Fickian diffusion 
of first order; between 0.43 and 0.85 indicates an anomalous transport; and above 0.85 
indicates a Case II transport of zero-order release (Ritger et al., 1987;Siepmanm et al., 
2001). 
In detail, standard diffusion can be described by the Fickian diffusion while Case II-
zero order nature indicates polymer relaxation and/or degradation of the particles causes 
the compound entrapped to be released (Ritger et al., 1987;Siepmanm et al., 2001;Silva et 
al., 2012). The anomalous transport is the combination of both phenomena, being both 
contributing equally for the compound release (Ritger et al., 1987;Siepmanm et al., 
2001;Silva et al., 2012). 
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According to Table V.4, the correlation coefficient (r2) for all n values was above the 
tolerable range (0.95), validating the obtained results. In absence and presence of HNE 
enzyme, the drug transport mechanism was considered as anomalous. In anomalous 
transport, also termed by non-Fickian diffusion, it is observed a coupling of Fickian diffusion 
(orange IV was released from the SF-NPs by simple diffusion) and polymer degradation 
(orange IV was released due to the SF structure relaxation/degradation), in which neither 
is predominant (Ritger et al., 1987;Siepmanm et al., 2001;Silva et al., 2012). 
The obtained n value was slightly larger in presence of HNE enzyme than in absence, 
however this difference is not significant, therefore the HNE presence only affects the 
diffusion coefficient but does not significantly influence the drug transport mechanism. 
Even so, to better evaluate this suggestion it is important to evaluate other HNE 
concentration. 
 In addition, in further studies we will assess the influence of the orange IV 
concentration in their release and drug transport mechanism. 
Finally, we proceeded to HNE inhibitor sivelestat incorporation at 100 µM of 
concentration. 
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3. Sivelestat Incorporation in SF-NPs and their HNE inhibition effect 
 
Sivelestat incorporation into the SF-NPs and their HNE inhibition effect was evaluated 
in order to recognize these nanoparticles potential as an anti-wrinkling agent. 
The initial characterization consisted in stability evaluation of the mean diameter and 
PDI over time, as presented in Figure V.6. 
 
 
Figure V.6. Stability evaluation of silk fibroin nanoparticles incorporated with 100 µM of HNE inhibitor 
sivelestat, on mean diameter in nanometres (nm) and polydispersity index value (PDI) along several weeks. 
 
According to previous evaluation of model-drug orange IV it was expected that the 
silk fibroin nanoparticles when loaded with sivelestat would present good stability of size 
and size distribution. However, results of Figure V.6 did not show this predictions. 
In addition, emulsion with sivelestat presented an increase of the particles mean 
diameter. In fact, with sivelestat we were not able to obtain nanoparticles since the mean 
diameter of the resulting particles was higher than 1 µm, and also the obtained PDI values 
was 1, showing that the solution was very polydisperse. 
 
To understand why this happen, we evaluate the surface charge of this sample at time 
of production (Figure V.7) and their formation and encapsulation efficiency (Table V.3).  
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Figure V.7. Surface charge evaluation of silk fibroin nanoparticles incorporated with 100 µM of HNE inhibitor 
sivelestat by zeta-potential determination in millivolts (mV) at time of production.  
 
 
The surface charge measurements highlight the stability difference between 
sivelestat and orange IV. In Figure V.7 it is possible to observe that SF-NPs with sivelestat 
present lower zeta-potential values than orange IV. 
Considering what we already discussed, this stability difference may be due to the fact 
the differences between sivelestat and orange IV structures. As suggested, the stability of 
orange IV may be related to the establishment of strong interactions with SF protein by 
sulphonic and azo groups, which lead to a more stable conformation, thus, to the control of 
size and size distribution of the SF-NPs. Since sivelestat does not possess azo groups, it is 
understandable that his stability effect is lower. 
 
Additionally, the formation and encapsulation efficiency of SF-NPs with sivelestat was 
also determined. In Table V.5, it is presented the obtained values for incorporation with 
sivelestat, without incorporation and with incorporation with the model-drug orange IV, to 
facilitate their comparison and further discussion. 
 
Table V.5. Silk Fibroin Nanoparticles yield production (formation efficiency) and encapsulation efficiency for 
incorporation of 100 µM of sivelestat. 
Sample 
SF-NPs Yield 
Formation Efficiency (%) 
SF-NPs  
Encapsulation Efficiency (%) 
SF-NPs (control) 60.097 ± 3.033 - 
SF-NPs loaded with 100 µM Orange IV 66.879 ± 2.147 91.446 ± 0.082 
SF-NPs loaded with 100 µM Sivelestat 99.685 ± 0.224 ~ 49.6 ± 5.6 
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Regarding the formation efficiency, the SF-NPs with sivelestat presented a higher 
value than without incorporation and with incorporated orange IV, which means that 
almost all SF molecules are being used in the nanoparticles formation. 
 
Still, the encapsulation efficiency obtained for this condition is lower than the 
predicted by orange IV incorporation. However, the sivelestat concentration that was 
incorporated in the SF-NPs (> 50 µM) is enough to inhibit HNE enzyme since this HNE 
inhibitor is very potent (Kawabata et al., 1991), which will be further proven in inhibition 
studies. In fact, according to Kawabata et al. studies, this drug showed an IC50 of 0.044 ± 
0.003 µM, when using succinyl-Alanine-Alanine-proline-phenylanine-p-nitroanilide (suc-
Ala-Ala-Pro-Phe-pNA) as substrate (Kawabata et al., 1991).  
It is also important to highlight that the method used to detect and quantify the free 
sivelestat (i.e. sivelestat not encapsulated in the SF-NPs) involved an extrapolation from the 
kinetic assays because sivelestat is very difficult to detection by simpler methods, like 
absorbance by UV-Vis. In this method, we detected the concentration of free sivelestat by 
measuring their inhibition effect on HNE enzyme, and then we determined sivelestat 
concentration by comparison and extrapolation with the standard HNE inhibition studies 
with sivelestat at various concentrations. 
Besides, since the encapsulation efficiency determination methods for sivelestat and 
orange IV are different, this obtained values cannot be correctly compared. Hence, this 
results only served to have an idea of the final characteristics of the developed SF-NPs 
incorporating sivelestat. 
 
In general, we have observed that the obtained results with sivelestat differ 
significantly from the predicted results with model-drug orange IV. As already discussed, 
this might be due to the differences between the orange IV and sivelestat structures, in 
which orange IV presented more stabilizing groups than sivelestat. 
 
Although the formation and encapsulation efficiency values obtained for SF-NPs 
incorporated with sivelestat were considered good, the mean diameter and PDI values of 
this particles, after production and over time, were not. In fact, the obtained characteristic 
of size and size distribution and their stability along time were not adequate, being 
necessary to conduct more experiences. Considering this, we suggest to evaluate other 
model-drug with more similarities to sivelestat or even to use sivelestat in further 
production, being important to take into account the cost of these suggestions. 
In addition, we also suggest that incorporation of stabilizers into the formulation 
would solve this instability problem, namely transcutol and SDS combination as previously 
proposed. 
CHAPTER V: INCORPORATION IN SF-NPs FOR TRANSDERMAL DELIVERY 
 
 
87 
 
Even so, we considered the studies with SF-NPs incorporating orange IV to be 
relevant since the obtained results which showed that orange IV really stabilizes the SF-NPs 
(mean diameter and PDI values of the SF-NPs incorporated with orange IV showed to be 
persistent over time) could be applied in the textile industry. In fact, silk and orange IV are 
extensively used in textile, in which Uddin et al. describes silk dying with an acidic dye like 
orange IV (Sah et al., 2010;Uddin et al., 2010). Considering this and in agreement with others 
studies, we suggest that application of SF-NPs incorporated with dyes, like orange IV, would 
enable improvement of colourability and enhancement of bleaching resistance (Hegemann 
et al., 2007;Mahltig et al., 2005;Siegfried, 2007). 
 
 
3.1. HNE Inhibition Studies of SF-NPs incorporated with Sivelestat  
 
Although, the SF-NPs incorporated with sivelestat did not present good stability 
results, we continued their characterization, namely their HNE inhibition effect. For that, we 
first conducted standard assays of HNE inhibition effect of the drug sivelestat. In other 
words, we assessed the sivelestat effectiveness as an inhibitor of HNE and potential anti-
wrinkling agent. 
The inhibition studies consisted in measuring the HNE activity at various 
concentrations of sivelestat, namely 0, 0.1, 0.25, 0.5, 1, 1.5, 2, 2.5 and 5 µM of sivelestat. This 
results are presented below, in Figure V.8. 
 
 
Figure V.8. Human Neutrophil Elastase (HNE) Inhibition studies with various concentration of the drug 
sivelestat (0.1, 0.25, 0.5, 1, 1.5, 2, 2.5 and 5 µM of sivelestat), at various concentrations of substrate N-
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide and at 0.5 U/mL of HNE. 
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The results of Figure V.8 highlight the effectiveness of sivelestat as a potent inhibitor 
of human neutrophil elastase, which agrees with previous publications (Aikawa et al., 
2011;Imokawa, 2008;Kawabata et al., 1991;Tsuji et al., 2001). In fact, it is possible to 
observe that at 5 µM of sivelestat, the HNE enzyme activity is completely inhibited. Hence, 
this shows the potential of sivelestat as an anti-wrinkling agent. 
 
Finally, HNE inhibition studies of the SF-NPs incorporating sivelestat were 
performed. According to the encapsulation efficiency previously discussed, these developed 
particles possess sivelestat at a higher concentration than 50 µM, which has been shown in 
Figure V.8 to be enough to cause HNE inhibition. 
In the following, we present the HNE inhibition studies of these developed particles 
with sivelestat incorporated, in Figure V.9. In this result, as controls we measured the HNE 
activity in buffer and in silk fibroin solution, being all in absence of sivelestat. 
 
 
 
Figure V.9. Human Neutrophil Elastase (HNE) Inhibition studies with silk fibroin nanoparticles incorporated 
with 100 µM of sivelestat, at various concentrations of substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide and at 0.5 U/mL of HNE. 
 
 
According to Figure V.9, it is possible to observe the HNE inhibition effect that SF-NPs 
incorporating sivelestat possess. In fact, the SF-NPs with sivelestat incorporated were able 
to completely inhibit the HNE enzyme, indicating their potential as anti-wrinkling agents. 
So, even that the final characteristics of the developed SF-NPs with sivelestat were not ideal, 
we can conclude that this is a good approach. 
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In addition, Figure V.9 also showed that silk fibroin did reduce the HNE activity, when 
dissolved in solution. Taking into account the Wharram et al. studies, the authors showed 
that silk wound dressing effectively remove HNE from the wound site (Wharram et al., 
2010). We, then, suggest that silk fibroin may possess the capability of inhibit the HNE 
enzyme, which enhances their potential when applied as nanoparticles. 
 
In conclusion, this results suggest that the silk fibroin nanoparticles incorporated 
with sivelestat can be used as anti-wrinkling agents since the developed particles were able 
to completely inhibit the HNE enzyme, which is extensively involved in wrinkle formation. 
by repeated UV irradiation and mild inflammation (Imokawa, 2008;Takeuchi et al., 2010). 
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Chapter VI: Structure Analysis of SF-NPs by FTIR 
Spectroscopy
 
 
 
The silk fibroin nanoparticles (SF-NPs) were produced by high-energy emulsification 
using high-pressure homogenization (HPH) method. Briefly, in this process oil-in-water 
samples are submitted to disruptive forces, such as hydraulic shear, intense turbulence and 
cavitation (Lovelyn et al., 2011). This forces break the oil and water initial phases, creating 
emulsion drops at nano range, which can ultimately lead to nanoparticles (Grebler et al., 
2010). Along this formation process, silk fibroin protein conformational changes may occur 
(Floury et al., 2000;Silva et al., 2012;Silva et al., 2012). Hence, in order to better understand 
the HPH emulsification process, the secondary structure of the developed SF-NPs were 
evaluated by attenuated total reflectance Fourier transform infrared (ATR-FTIR) 
spectroscopy, being this technique further detailed in Annex X. 
 
A range of conformations has been found in silk secondary structure, such as, random-coil, Ⱦ-sheets, Ⱦ-turns, Ƚ-helices and 310 helices (Chen et al., 2001). The silk high 
conformational variability due to their high content of glycine, designating silk as a 
polymorphic protein (Wilson et al., 2000). The dominant secondary structure of silk differs 
according to the environment of the protein, such as pH, temperature, ions presence and 
absence, energy involved, and others (Wilson et al., 2000), being important to understand 
the conditions that lead to conformational changes of the secondary protein. 
The unordered and rather unstable conformation, usually termed as random-coil, 
results from non-repetitive sequences (Kong et al., 2007;Tsukada et al., 1994), whereas the 
other structures are established due to the repetitive motifs (Rabotyagova et al., 2010).  
A more stable structure is Ⱦ-sheet conformation, which is characterized by folded 
chains lied alongside of each other, in a parallel (sheets point in the same direction) or anti-
parallel orientation (sheets point in opposite directions) (Chen et al., 2001;Tsukada et al., 
1994). The Ⱦ-sheet folding is nucleated and envisioned with reverse turn formations, the Ⱦ-
turns (Fuller et al., 2009). This Ⱦ-turns structures, also called by Ⱦ-bends, are arranged end-
to-end of each Ⱦ-strand, enabling the Ⱦ-sheets final conformation, connecting this two 
structures to the same conformation Ⱦ-sheets (Vollrath et al., 2001). The Ƚ-helix conformation is also a stable structure, formed by winding the 
polypeptide backbone into a tightly packed right-handed helix, i.e. folded in clockwise 
direction (Rabotyagova et al., 2010). Similar to Ƚ-helices conformation, there is the 310 
Helices, which are a more compact conformation, folded in counter clockwise direction 
(Vollrath et al., 2001). 
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Silk in a natural source is composed by Ⱦ-sheet crystalline segments with alternation 
with amorphous segments of random-coil (Rabotyagova et al., 2010). Whereas silk fibroin 
particles prepared by mechanical mixing and self-assembly process is predominantly composed by Ⱦ-sheets (Zhao et al., 2013). In fact, their application as drug delivery systems is improved because of the crystalline Ⱦ-sheets formation, since it increases encapsulation 
efficiency and enables control of the drug release kinetics (Tudora et al., 2013). 
 
There are a couple of normal modes of movements and vibration that proteins can 
achieve, which depends of  the several internal coordinates of  the protein, namely the bond 
lengths and bond angles (Barth et al., 2002). Since there are a vast number of normal modes, 
the vibrational spectrum is complex in which many of the vibrational bands overlap, 
preventing accurate analysis (Barth et al., 2002). As solution, it is possible to select a 
spectral region suitable for the information that we expect to extract (Barth et al., 2002). 
Mainly, these selected regions present a spectrum dominated by protein repeat units 
with the same kind of normal mode vibration (Barth et al., 2002). The proteins repeat units 
can lead to nine characteristic IR absorption bands, namely amide A, B, and I to VII (Kong et 
al., 2007). 
 
As preliminary screening tool, the position of amide I, II and III bands of IR spectra 
was used identifying the prevailing structure taken by the silk fibroin. The amide I band is 
between 1600 cm-1 and 1700 cm-1 (Kong et al., 2007) and is mainly dominated by signals of 
the backbone C=O stretching vibrations (Barth et al., 2002;Kong et al., 2007); amide II and 
III are attributed to the C-N stretching and N-H bending (Kong et al., 2007), and are detected 
in 1480 to 1575 cm-1 and 1229 to 1301 cm-1, respectively (Kong et al., 2007). 
The position of these bands can also specify the main conformation of the silk fibroin, 
namely for amide I, 1620-1638 cm-1 indicates Ⱦ-sheets and 1639-1647 cm-1 indicates 
random-coil (Wilson et al., 2000); for amide II, 1515-1530 cm-1 indicates Ⱦ-sheets and 1534-
1540 cm-1 indicates random-coil (Ha et al., 2005;Miyazawa et al., 1960); and for amide III, 
1229-1244 cm-1 indicates random-coil and 1265-1270 cm-1 indicates Ⱦ-sheets (Ha et al., 
2005;Tsukada et al., 1994). 
The obtained results of this initial analyse for silk fibroin solution (before 
emulsification process) and for silk fibroin nanoparticles with and without incorporation 
(after emulsification process) are presented in graph of Figure VI.1. For better elucidation, 
the respective band of amide I, II and III is also indicated. 
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Figure VI.1. FTIR spectrum of the three principal amide (amide I, II and III) of silk fibroin protein before and 
after HPH emulsification process, in which the random-coil and Ⱦ-sheets secondary structure is presented. 
 
 
According to amide I and II, the silk fibroin nanoparticles (after HPH emulsification 
process) present higher signals for Ⱦ-sheets, suggesting this secondary structure as 
dominant in these sample, wherein the silk fibroin solution (before HPH emulsification 
process) presents high signal for random-coil in amide I spectra. However according to 
amide II region, this sample presents minor signal for random-coil, presenting a higher 
signal for Ⱦ-sheets structure. Regarding the amide III, all samples present higher signals for 
random-coil structure, which is discrepant to the amide I and II results. 
As result of these discrepancies, further studies were conducted, in order to better 
understand the mechanisms involved in HPH emulsification and the conformational 
changes of the secondary structure that can occur. 
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Amide I band (1600 cm-1 and 1700 cm-1) is considered the most prominent and 
sensitive vibrational bands (Kong et al., 2007). This amide I is mainly dominated by signals 
of the backbone C=O stretch vibrations (Barth et al., 2002), which indicates the peptide 
linkages and their frequencies components closely correlate to the secondary structure 
(Kong et al., 2007). According to this and the fact that amide I spectrum is not significantly 
affected by side chain vibrations (Rabotyagova et al., 2010), we selected the amide I spectral 
region for silk fibroin protein secondary structure deeper analyse by ATR-FTIR 
spectroscopy. For that, region between 1600 cm-1 and 1700 cm-1 was deconvulated into 
discreet components indicating the specific secondary structure. The assignment of the 
peaks to a respective secondary structure was based in Kong et al., 2007 and Dong et al., 
1992 studies (Dong et al., 1992;Dong et al., 1992;Kong et al., 2007). 
For amide I, peaks in the range of 1616-1643 cm-1 and 1689-1698 cm-1 were indicative 
of Ⱦ-sheets structures, 1667-1688 cm-1 indicated Ⱦ-turns, 1644-1650 cm-1 indicated 
presence of random-coil conformation, 1652-ͳ͸ͷ͹ were assigned to Ƚ-helices 
conformations, and 1658-1666 cm-1 were indicative of 310 Helix structure. 
The results of deconvulation of amide I is presented in the following graph, Figure 
VI.2. In this figure, the secondary structures content (in percentage) of each sample (before 
and after HPH emulsification) is displayed. This result will allow us to better understand the 
mechanism and conformational changes that may occur during this nanoparticles formation 
process, and to compare the nanoparticles without and with incorporation of orange IV and 
sivelestat. 
 
 
Figure VI.2. Results from the deconvulation of amide I region (1600 and 1700 cm-1) of the FTIR spectrum of silk 
fibroin protein before and after HPH emulsification process. 
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As already mentioned above, forces involved in high-pressure homogenization (HPH) 
are very similar to the ones involved in ultrasonication, so we hypothesised that the silk 
fibroin behaviour in both methods is similar (Bang et al., 2010;Lovelyn et al., 2011). 
According to other studies, through nanoparticles formation by ultrasonic emulsification, silk fibroin protein acquire mainly Ⱦ-sheets conformation (Silva et al., 2012;Silva et al., 
2012). In detail, this sonochemical process increases the proximity of the molecular chains, 
which promotes crystallinity (Silva et al., 2012;Silva et al., 2012). Therefore, we 
hypothesized that crystalline conformation, namely Ⱦ-sheets structure, increases along the 
nanoparticle formation by HPH emulsification process. 
 In fact, results presented in Figure VI.2 agree with this hypothesize since the content 
of Ⱦ-sheets increased with the high-pressure homogenization process. This is noticed because Ⱦ-sheets content in silk fibroin solution (before HPH emulsification) to the silk 
fibroin nanoparticles (after HPH emulsification process), increased from ~40% to 65%.  
In addition, the same effect is observed for silk fibroin nanoparticles incorporated 
with a drug, in which, incorporation with orange )V and sivelestat presented Ⱦ-sheets 
content of ~67% and ~57%, respectively. This difference might be related to the fact that 
orange IV possess a the capability to stabilize the SF by establishing hydrophobic interaction 
and van der Waals forces with the SF structure due to the azo (N=N) and sulphonate groups 
(S=O) whereas sivelestat only has the sulphonate group (Uddin et al., 2010). Besides 
dissolution of orange IV in SF causes decrease of pH, since orange IV is an acid dye. This 
acidic environment causes protonation of the carboxyl groups on side chains of SF, 
decreasing repulsions and also leading to stronger hydrophobic interactions (Matsumoto et 
al., 2006). According to this, orange IV is capable to stabilize the SF, and therefore promoting 
a higher crystallinity content. 
 
Furthermore, the random-coil conformation decreased with the HPH emulsification 
process, from ~25% of random-coil content in silk fibroin solution to ~23% for silk fibroin 
nanoparticles without incorporation, and random-coil content of SF-NPs incorporated with 
orange IV and sivelestat was ~14% and ~16%, respectively. The random-coil opposite behaviour to the Ⱦ-sheets content, suggested that random-coil may be conformational changing to Ⱦ-sheets. 
 The same is applied to Ⱦ-turns conformation, and since Ⱦ-turns connect end-to-end 
the Ⱦ-sheets, it may also imply that the Ⱦ-sheets structures are becoming elongated and 
extended. Even so, the proximity of the peaks range of Ⱦ-turns (1667-1688 cm-1) to the range of Ⱦ-sheets (1689-1698 cm-1) can also lead to some difficulty in peaks assignment. 
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Finally, the 310 Helix content decreased from silk fibroin solution (~18%) to silk 
fibroin nanoparticles (~7), which suggested a conformational change to a more stable structure, Ⱦ-sheets. However, SF-NPs incorporated with orange IV and sivelestat showed a 
smaller decrease of 310 Helix content, this may suggest that these structures are less stable 
than the SF-NPs without incorporation. The decrease of 310 Helix content for SF-NPs 
incorporated with sivelestat was less significant than with orange IV because this last drug 
has a higher capability of stabilize the SF-NPs. 
 
 The FTIR spectroscopy results showed that the secondary structure of the silk fibroin 
changed during the high-pressure homogenization emulsification process, implying that 
this process possess the same behaviour of ultrasonication. The silk fibroin crystallinity 
content increased along the nanoparticle formation process by HPH, since the random-coil 
and other structures conformational changed to Ⱦ-sheets after this emulsification process. 
Therefore, the silk fibroin associated in nanoparticles showed a more stable structure, 
which is very promising as drug delivery systems, specifically for the intended topical anti-
wrinkling application. 
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Chapter VII: General conclusions and future perspectives 
 
The goal of this dissertation was the development and characterization of silk fibroin 
nanoparticles incorporated with a human neutrophil elastase inhibitor, sivelestat, for 
topical application as an anti-wrinkling agent. These SF-NPs are intended to effectively 
entrap sivelestat at a therapeutic concentration in order to successfully inhibit the HNE 
enzyme present in the skin, preventing wrinkles formation induced by UV radiation. 
Furthermore, these nanodevices should be able to penetrate the skin stratum corneum, in 
order to effectively inhibit the HNE degradation of the extracellular matrix, consequently 
preventing the wrinkles formation. 
 
1. Final Remarks 
 
To simplify, the final remarks of this dissertation work are summarized above. 
For silk fibroin nanoparticles optimization process by the high-energy methods 
ultrasonication and high pressure homogenization (HPH) (chapter IV), the final remarks are 
the following: 
 NPs production requires a large input of energy, in which we only effectively 
obtained uniform smaller NPs when the disruptive forced involved are sufficient to control 
the nanoemulsion and NPs formation. 
 Increase of SF concentration and decrease of n-dodecane content allows better 
control of the NPs structure, which facilitates the emulsification process and enables 
production of smaller NPs with a uniform distribution. 
 For HPH, the increase of number of cycles leads to uniform smaller NPs until a given 
cycle and pressure. At this point, it occur saturation-like behaviour where it negatively 
affects the emulsion and the NPs production. 
 The best NPs characteristics was obtained when using 10 g/L of SF, at 20/80 of n-
dodecane/RSF solution for 22 homogenization cycles with double-stage HPH emulsification 
(APV-ʹͲͲͲ™). At well-controlled conditions, the emulsification HPH method was 
considered reproducible. 
 The origin of SF, namely the silkworm Bombyx mori, can extensively affect the 
obtained product and as consequence it produced different SF-NPs, being important to take 
all the methods variables into account. 
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Finally, the main conclusions obtained from silk fibroin nanoparticles incorporation 
studies at the optimized conditions (chapter V) and their structural analysis by FTIR 
(chapter VI) are presented above: 
 Regarding incorporation of stabilizers into the formulation, transcutol showed to be 
more effective in stabilizing the size and size distribution over time and higher NPs yield 
(formation efficiency) was obtained for SDS. 
 The model-drug orange IV showed to stabilize the size and size distribution over 
time, wherein incorporation of 100 µM of orange IV showed to be more effective. We 
considered this concentration as ideal for sivelestat incorporation in the SF-NPs. 
 Orange IV releases from SF-NPs showed to be controlled at some extent. In this 
condition, we also observed incomplete release of orange IV, which could suggest instability 
of SF-NPs. However, results also suggest that HNE enzyme might cleave the orange IV, 
affecting their release detection. 
 The drug transport mechanism involved in orange IV release from SF-NPs was 
considered to be anomalous (Fickian diffusion and polymer degradation/relaxation), in 
which it showed not to be affected by HNE enzyme at 0.5 U/mL. 
 Incorporation of sivelestat in SF-NPs differed significantly from the predicted 
results using the model-drug orange IV, suggesting that orange IV was not the ideal model-
drug for this project. Even so, results for orange IV could be applied in the textile industry 
to improve colourability and bleaching resistance. 
 SF-NPs incorporated with sivelestat showed a good formation and encapsulation 
efficiency and successfully inhibit the HNE enzyme, enhancing their potential use as anti-
wrinkling agents. 
 During HPH emulsification process, the SF protein acquires mainly Ⱦ-sheets content, 
due to probable shifting of random-coil conformation to more stable structures. 
In conclusion, SF-NPs produced by HPH method showed to be a stable and effective 
drug delivery system, and when incorporating sivelestat showed to successfully inhibit HNE 
enzyme being very promising nanodevice for topical anti-wrinkling application. 
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2. Future Work 
 
Although the obtained results in the experimental work of this dissertation were 
satisfactory, further studies should be carried out for a more precise work evaluation. Those 
potential future studies are presented below: 
 Evaluate the stabilizing effect when combining co-surfactant transcutol with 
surfactant SDS into the SF-NPs formulation. 
 Measure and compare the HNE activity at various conditions (for example, in SF 
solution and in orange IV solution) to evaluate the possibility of HNE cleavage of orange IV. 
 Study the developed SF-NPs morphology, for example by transmission electron 
microscopy (TEM) or scanning transmission electron microscopy (STEM). 
 Optimize a better detection method for sivelestat, for example by high-performance 
liquid chromatography (HPLC). 
 Optimize the production process of SF-NPs incorporated with sivelestat, namely the 
optimal concentration to incorporate. 
 Evaluate the in vitro sivelestat release from SF-NPs at various parameters (such as 
pH, temperature and HNE concentration), for example by dialysis bag method and/or by 
confocal analysis, in which sivelestat could be associated to a fluorescent dye. 
 Conduct molecular simulations of the behaviour of SF protein during HPH 
emulsification process and of sivelestat release from SF-NPs. 
 Evaluate the in vitro cytotoxicity of the developed SF-NPs. 
 Evaluate the transdermal delivery of the developed SF-NPs and their HNE inhibition 
effects by in vitro histological penetration studies 
 Evaluate the developed SF-NPs as an anti-wrinkling agent by in vivo histological 
studies. 
A number of valuable results were obtained in this dissertation, and hopefully may be 
further used in future investigations, taking into account that SF-NPs can be used for other 
applications. 
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Annexes 
Annex I. Bombyx mori Silk Fibroin Amino Acid Composition. 
Table Annex.1. Amino acid composition expressed as mol % of Bombyx mori silk fibroin, quantified by High-
performance liquid chromatography (HPLC) after acid hydrolytic treatment (24 hours of 6M HCl, at 105°C, 
under vacuum) and analysed according to the AccQ-Tag Method, published in Vasconcelos et al., 2008. 
 
  Amino acid 
Quantity in silk 
fibroin (mol %) 
Aspartic acid (Asp) 1.67 
Serine (Ser) 11.48 
Glutamic Acid (Glu) 1.37 
Glycine (Gly) 43.68 
Histidine (His) 0.20 
Arginine (Arg) 0.62 
Threonine (Thr) 0.96 
Alanine (Ala) 29.34 
Proline (Pro) 0.67 
Cysteine (Cys) 0.10 
Tyrosine (Tyr) 5.30 
Valine (Val) 2.23 
Methionine (Met) 0.10 
Lysine (Lys) 0.33 
Isoleucine (Iso) 0.66 
Leucine (Leu) 0.58 
Phenylanine (Phe) 0.72 
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Annex II. Silk Fibroin Hydrogels formation. 
 
SF hydrogels are determined by silk fibroin concentration, temperature, pH 
(Matsumoto et al., 2006), presence of Ca2+ and K+ (Kim, U et al., 2004), and is even related to 
RSF preparation process (Ayub et al., 1993). Briefly, Matsumoto studies showed that 
increasing SF concentration and temperature, the gelation time decreases, i.e. leads to gel 
formation (Matsumoto et al., 2006); and Ayub and co-workers suggested that reduction of 
SF molecules movement and formation of hydrogen bonds increases and stabilizes Ⱦ-sheets, 
leading to gel formation (Ayub et al., 1993). In more detail, lower pH (2 to 4) and increasing 
pH (6 to 9) decreases gelation time, since lowering pH (2 to 4) causes protonation of the 
carboxyl groups on SF side chains, decreasing repulsions and consequently stronger 
hydrophobic interactions are established, leading to gel formation; and increasing pH (6 to 
9) triggers electrostatic interactions between charged amino and carboxylic groups, also 
leading to gelation but at a lower rate (Matsumoto et al., 2006). Lastly, Ca2+ also increases 
these interactions, also leading to gel formation (Kim, U et al., 2004). 
SF gels can also be formed by vortexing, sonication, by applying electrical current 
(Rockwood et al., 2011), or induced by supplementation with poly(ethylene oxide) (PEO) 
(Jin et al., 2004) or poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene 
glycol (commonly named as poloxamer 407) (Vepari et al., 2007), or sodium dodecyl 
sulphate (SDS) (Wu, X et al., 2012). In particular, PEO is a biocompatible polymer, which 
reassembles to a surfactant (Jin et al., 2004), and facilitates interactions among SF protein 
and increasing Ⱦ-sheets content (Kim, U et al., 2004); and poloxamer 407 and SDS also 
increases these interactions, also leading to gel formation (Wu, X et al., 2012). However, 
poloxamer 407 is non-biodegradable and presents minor effect in gel formation, hence is 
not considered as an ideal gel inducer, whereas SDS is approved by FDA and highly 
recommended (Wu, X et al., 2012). 
 
  
ANNEXES 
 
109 
Annex III. Equipment’s used in this work. 
Table Annex.2. List of equipment used through the experimental work of this dissertation with their basic 
description, such supplier, the method which was associated with and its use in the experimental work. 
  
Name of the equipment Supplier Associated-method Use ʹͲ k(z Vibrocell ™ CV ͵͵ 
- Probe type ultrasound 
source  fitted with a 3 mm 
diameter titanium micro-tip 
Sonics and Materials 
Inc., 
Connecticut, USA 
Ultrasonic 
emulsification 
Nanoemulsion and NP 
production 
EmulsiFlex™-C3 Avestin, 
Ottawa, Canada 
High Pressure 
Homogenization 
(single-stage system) 
Nanoemulsion and NP 
production 
APV-ʹͲͲͲ™ SPX Flow Technology, APV Manufacturing, 
 Poland 
High Pressure 
Homogenization 
(double-stage system) 
Nanoemulsion and NP 
production 
ZetaSizer Nano ZS 
(with ZetaSizer software 
version 7.01) 
Malvern   Instruments   
Ltd., 
Worcestershire, United 
Kingdom 
Dynamic Light 
Scattering (DLS); 
Laser   Doppler   
Anemometry (LDA) 
NPs 
characterization 
SynergyMx    with    Genͷ™ Microplate 
Data  Collector  and  
Analysis  Software 
Bio-Tek Instruments, Inc.,  
Vermont, USA 
Ultraviolet-Visible 
(UV-Vis) 
Spectrophotometry 
HNE studies and 
inhibition; 
Calibration curves; 
NPs Characterization 
Jasco FT/IR 4100 
spectrometer equipped with 
attenuated total reflectance 
(ATR) accessory 
Jasco, Inc., 
Easton, EUA. 
Fourier Transform 
Infrared  (FTIR) 
Spectroscopy 
NPs characterization 
Allegra® X-15R Centrifuge 
with an FX6100 rotor 
Beckman Coulter, Inc., 
California, EUA. 
Ultracentrifugation NPs characterization 
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Annex IV. Calibration curve of Regenerated Silk Fibroin by Bradford method. 
 
Figure Annex. 1. Calibration the curve of regenerated silk fibroin by Bradford method, used in further 
quantification of this protein along this work. The determined equation is y=-0.0249x2 + 0.304x + 0.0357, with 
r2 of 0.9971. 
 
Annex V. Information of the Stabilizers used in this work. 
Table Annex.3. Chemical basic information (molecular weight, molecular formula and structure) of the 
stabilizers used along this work, namely poloxamer 407, transcutol, tween 80 and SDS, retrieved from the 
suppliers document sheet. 
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Name Molecular Weight 
Molecular 
Formula 
Structure 
Poloxamer 407 
(9,840 to 14,600) 
~ 1,260 g/mol  
(C3H6O.C2H4O)n 
 
Transcutol 134.17 g/mol C6H14O3  
Tween 80 Mn ~1,310 Da C64H124O26 
 
SDS 288.38 g/mol CH3(CH2)11OSO3Na 
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Annex VI. Information of Orange IV and Sivelestat used in this work.  
Table Annex.4. Chemical basic information (molecular weight, molecular formula and structure) of orange IV 
and sivelestat, retrieved from the suppliers document sheet. 
 
 
Annex VII. Dynamic Light Scattering (DLS) Method. 
In this experimental work, the developed nanoparticles characterization according to 
size and size distribution was determined by dynamic light scattering (DLS), also known as 
photonic correlation spectroscopy (PCS), which measures the Brownian motion of the 
particles, and the diffusion coefficient is determined by Stokes-Einstein equation (Bunjes, 
2005), presented above. ܦ = K. T͵. π. d 
 
Equation Annex.1. Stokes-Einstein equation used to determinate the diameter of the particles, where D, d, K 
and T represent the diffusion coefficient, the diameter of the particles, the Botlzman constant and the 
temperature in Kelvin, respectively. Based in Bunjes, 2005 publication. 
 
  
Name 
Molecular 
Weight 
(g/mol) 
Molecular 
Formula 
Structure 
Orange IV 375.38 NaC18H14SN3O3 
 
Sivelestat sodium 
salt hydrate 
434.46 C20H22N2O7S 
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Annex VIII. Laser Doppler Anemometry (LDA) Method.  
In this experimental work, the developed nanoparticles surface charge 
characterization was determined by laser Doppler anemometry method according to zeta-
potential. In this method, the particles are submitted to weak electric field (Malvern, 2005), 
resulting in frequency (Doppler) shift, then their electrophoretic mobility is indirectly 
determined according to Henry equation (Bunjes, 2005), presented above. 
 µ� = ʹ. ɂ. Ƀ−. fሺKaሻ͵. Ʉ  
 
Equation Annex.2. Henry equation used to determinate the electrophoretic mobility of the particles, where µe, ɂ, Ƀ, Ʉ and fȋKa) represent the electrophoretic mobility, dielectric potential, zeta-potential, role of Henry and 
viscosity of the medium, respectively. Based in Bunjes, 2005 publication. 
 
Annex IX. Calibration curve of compound Orange IV.  
 
Figure Annex. 2. Calibration the curve of orange IV, used in further quantification of this compound along this 
work. The determined equation is y=-0.0043x + 0.0155, with r2 of 0.9961. 
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Annex X. Fourier transform infrared (FTIR) Spectroscopy Method.  
 
Being one of the oldest and well established experimental techniques for protein 
secondary structure analysis (Hsu, 1997;Kong et al., 2007), infrared (IR) spectroscopy is 
based in the fact that each molecule absorbs distinct wavelength (Kong et al., 2007). In IR 
spectroscopy samples are submitted to infrared radiation, causing molecular vibration, 
which can be detected (Barth et al., 2002). Emerge of Fourier transform infrared (FTIR) 
spectroscopy revolutionised the IR technique by enabling wavenumber detection 
simultaneously and massive data acquisition, making it a faster and reliable technique 
(Barth et al., 2002;Kong et al., 2007). Coupling of attenuated total reflectance (ATR) 
accessory to FTIR allows IR radiation deeper penetration, being used for thick or highly 
absorbing solid and liquid materials (Hsu, 1997). In ATR method a thin protein film (portion 
of the lyophilized sample) was deposited on an internal reflection element (IRE), a crystal 
(Barth et al., 2002;Kong et al., 2007), then the IR radiation passes through the IRE material, 
and interacts with the sample material at the interface of these two materials (Hsu, 1997).  
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